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ABSTRACT
The basal forebrain (BF) is comprised of several nuclei including the substantia
innominata, medial septum, nucleus basalis and diagonal band of broca which are
involved in cognitive functions including attention, motivation, and arousal. BF neurons
are particularly vulnerable to dysfunction and degeneration in aged humans and, more
dramatically, in diseases such as Alzheimer's disease (AD). Age-related BF dysfunction
may reflect diminished afferent regulation as well as an altered local glial environment.
Our lab has previously shown reduced orexin/hypocretin innervation of BF in aging, a
phenomenon that may link afferent dysfunction with altered microglial homeostasis.
There is little research examining these relationships involving afferent neuronal and glial
cell populations in the BF as it relates to aging. The purpose of this study is to compare
specific neuronal and glial populations to identify anatomical factors susceptible to agerelated homeostatic dysfunction in the BF.
Several lines of evidence demonstrate the responsiveness of the BF to
homeostatic stimuli including food related stimuli. Using a food-paired stimulus to
examine effects of aging on physiologically-relevant afferent stimulation of this area, we
deposited the retrograde neuronal tracer, cholera toxin B (CTb) in BF of aged (26-28
months) and young (2-3 months) F344/Brown Norway F1 hybrid rats and trained them
for 7 days. We then combined neural tract-tracing with functional and phenotypic
markers of activation to elucidate neural circuits that may underlie age-related loss of
activation of BF neurons using immunohistochemistry.
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Previous research in our lab has shown that a homeostatically- relevant circuits
involving the orexin neuropeptide, show age-related degredation which may be linked to
BF dysregulation. Additionally, orexin loss is linked to conditions such as narcolepsy,
anorexia nervosa, age-related cognitive decline, and age-related neurodegenerative
diseases, such as AD. To show that loss of orexin afferents affects inflammation in the
BF via microglial dysregulation, we administered a miRNA-expressing lentivirus
designed to knock down orexin expression (LV-PPOX) in the BF in young rats. We then
analyzed phenotypic changes in microglia using immunohistochemistry and ELISA
against a panel of pro- and anti-inflammatory cytokines. Changes in morphological and
cytokine correlates of microglial activation following orexin loss can be seen in animals
administered LV-PPOX. Together, these studies compare specific neuronal and glial
populations of young and aged rats to identify anatomical factors susceptible to agerelated dysfunction.
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CHAPTER 1. GENERAL INTRODUCTION

1.1 Significance
Alzheimer’s disease (AD) is distinguished by progressive brain atrophy which
leads to memory loss, attentional deficit, homeostatic imbalance and sleep disturbance.
Approximately 15-20% of Americans over the age of 65 will develop mild cognitive
impairment (MCI) and 32% of those individuals go on to develop AD (Roberts &
Knopman, 2013; Ward, Tardiff, Dye, & Arrighi, 2013). MCI is an age-associated
memory impairment of which symptoms fall between normal age-related cognitive
decline and severe dementia, but the neuronal anatomical correlates which cause this
stepwise cognitive decline in aged individuals have yet to be fully understood. Moreover,
the pathology which drives more severe forms of cognitive impairment which resembles
a more severe form of MCI, such as AD, is still unknown.
Longitudinal studies comparing basal forebrain (BF) atrophy with Aβ deposition
reveal abnormal degeneration in BF has been shown to precede the onset of AD (Schmitz
& Nathan Spreng, 2016). In particular, the degeneration of the substantia innominata
(SI)/ nucleus basalis of Meynert (NBM) nuclei of the BF is a hallmark of AD, and is
associated with normal cognitive aging (Barragán Martínez, García Soldevilla, Parra
Santiago, & Tejeiro Martínez, 2019; Kawas, Gray, Brookmeyer, Fozard, & Zonderman,
2000; Schmitz, Mur, Aghourian, Bedard, & Spreng, 2018). Evidence has shown the BF is
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particularly vulnerable to neuronal dysfunction and moderate degeneration in aged
humans which occurs more often in MCI and diseases such as AD
(Fernández-Cabello et al., 2019; M. Grothe, Heinsen, & Teipel, 2013; Rossini, Rossi,
Babiloni, & Polich, 2007; Wolf et al., 2014). This suggests that dysfunctional anatomical
correlates of the BF, specifically in the SI/NBM, may be a key component in the spread
and development of mild cognitive impairments and, in more severe cases, AD. This
study investigates age-related changes in basal forebrain afferent and neuronal cell
populations to identify vulnerable neuronal populations involved in age-associated
cognitive decline and dysfunction. Results from this study will contribute toward the
efforts to identify targets of age-related dysfunction which may play a role in age
associated MCI and homeostatic dysfunction exacerbated during age-related
neurodegenerative diseases, such as AD.

1.2 Alzheimer’s Disease
Discovered in 1906 by Alois Alzheimer, AD was defined as a combination of
cognitive deficits, psychiatric symptoms, and microscopic brain abnormalities (Roberson
& Mucke, 2006). It was later understood that AD was a neurodegenerative disease,
characterized by the loss of vulnerable cell populations, that results in widespread brain
atrophy beginning in the BF (Kerbler et al., 2015). Other hallmarks of the disease include
the extracellular deposition of amyloid-β (Aβ) and intracellular accumulation of tau.
Today, AD affects more than 5.4 million people over the age of 65 in the U.S., and is
estimated to affect 50 million individuals worldwide, a number that will escalate in the
coming decade (Hebert, Weuve, Scherr, & Evans, 2013; Massoud & Gauthier, 2010).
Moreover, the burden of these behavioral and psychologic changes falls greatly on both
2

care takers and the economic system, especially as the elderly population continues to
grow. The behavioral changes associated with AD are distinguished by a progressive
deterioration of memory, homeostatic balance, cognition, olfactory discrimination,
learning and judgement (Auld, Kornecook, Bastianetto, & Quirion, 2002; Cacquevel,
Lebeurrier, Cheenne, & Vivien, 2005; Gutiérrez et al., 1999; Mandrekar-Colucci &
Landreth, 2012). However, our understanding of the development of the disease remains
elusive and how the disease develops and progresses it is not yet fully understood.
AD has both genetic and environmental components which both can contribute to
the development and progression of the disease. Genetically, AD has two distinct forms,
familial and sporadic. Whereas familial AD is known to run in families, a majority of
cases arise as late-onset sporadic which has no familial link. The familial form is due to
mutations in three major genes including the amyloid precursor protein (APP) gene,
presenilin1 (PSEN1) gene and presenilin 2 (PSEN2) gene(Armstrong, 2013; S. E.
Hickman, Allison, & El Khoury, 2008; Mawuenyega et al., 2010). Interestingly, only 1%
of cases are associated with genetic mutations such as APOE ɛ4. Most cases of AD
(~99%) are considered sporadic with the major risk factor being age (Barragán Martínez
et al., 2019; Hebert et al., 1995; Kawas et al., 2000). The development of sporadic AD
usually occurs between the ages of 60-65, but the role of aging pathology is unclear
(Dorszewska, Prendecki, Oczkowska, Dezor, & Kozubski, 2016; Lista et al., 2015).
Many other factors may contribute to determining the sporadic AD form including
anatomical changes, neuroinflammation, and aging. However, it is not yet known what
specific underlying mechanisms and anatomical changes separate healthy normal aging
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individuals from those who go on to develop AD. Moreover, the initial stages of AD,
important in identification and prevention of AD, are not well understood.
1.2.1 Anatomical Correlates
Brain regions that are associated with higher cognitive functions, such as the BF
and regions of BF innervation including the neocortex and hippocampus, are most
vulnerable to the neurodegenerative characteristic pathology of Alzheimer’s disease
(McKinney, Coyle, & Hedreen, 1983; Whitehouse et al., 1982). Post-mortem studies
reveal enlarged ventricles, cortical atrophy, and temporal atrophy including regions of the
BF and hippocampus in patients diagnosed with AD (Bobinski et al., 1999; Hampel et al.,
2018; Kerbler et al., 2015; M. M. Mesulam et al., 2002; M. Marsel Mesulam, 2004;
Wood et al., 1983). Evidence has shown the BF is particularly vulnerable to neuronal
dysfunction and moderate cell loss in aged humans, which occurs more dramatically in
diseases such as AD (Fernández-Cabello et al., 2019; M. Grothe et al., 2013; Wolf et al.,
2014). Recent research suggests that the BF degeneration may predict the onset of AD
(Fernández-Cabello et al., 2019; Schmitz & Nathan Spreng, 2016). Moreover, changes in
the BF volume predict the mild cognitive decline of normal aging patients and the
cortical neuronal degeneration and cognitive decline seen in AD patients (FernándezCabello et al., 2019; M. Grothe et al., 2013; Schmitz & Nathan Spreng, 2016; Teipel et
al., 2018; Wolf et al., 2014). This suggests that dysfunctional anatomical correlates of the
BF may be a key component in the spread and development of AD.
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1.2.2 Cholinergic Hypothesis
The discovery of the first neurotransmitter, Acetylcholine (ACh), in the early 20 th
century eventually led to a revolutionary change in the understanding of AD (H. FerreiraVieira, M. Guimaraes, R. Silva, & M. Ribeiro, 2016; Loewi, 1921). Following the
histological analysis of several brains of patients with AD, researchers found that there
was a severe deficit in cholinergic projections (P. Davies & Maloney, 1976). Specifically,
the discovery of cholinergic cell loss in cortical neurons responsible for the innervation of
the SI/NBM of the BF, in patients with AD, established cholinergic neuronal
degeneration as a major symptom of AD (P. Davies & Maloney, 1976; M. M. Mesulam,
1976; Whitehouse, Price, Clark, Coyle, & DeLong, 1981). Moreover, it was found that,
in patients with AD, there was a significant decrease in the enzyme responsible for the
synthesis of ACh, choline acetyltransferase (ChAT), and a notable decrease in choline
reuptake in the BF and hippocampus (Contestabile, 2011; Elaine K. Perry, Gibson,
Blessed, Perry, & Tomlinson, 1977). Electrophysiological studies showing that there was
a significant decrease in ACh release in cortical brain slices from AD patients which
further supported the idea that cholinergic dysfunction plays a key role in AD (Nilsson,
Nordberg, Hardy, Wester, & Winblad, 1986).
Cumulatively, these discoveries have led to the “cholinergic hypothesis” which
states that the dysfunction of cholinergic neurons contributes to the cognitive decline in
patients with AD (Raymond T. Bartus, 2000). We now know that a decline in ACh
release by cholinergic neurons, specifically in the BF, plays an important role in
cognitive impairment and attentional processing. The disruption of these cholinergic
inputs leads to behavioral and attentional deficits in rats similar to symptoms of AD in
5

humans (Everitt & Robbins, 1997; Muir, Dunnett, Robbins, & Everitt, 1992). Moreover,
the decline of BF cholinergic neurons and associated cognitive impairments can be seen
in both normal aging and to a greater extent in aged individuals with AD (Raymond T.
Bartus, Dean, Beer, & Lippa, 1982). Therefore, the loss of the cholinergic neurons in the
BF during aging has been accepted as a major factor in cognitive dysfunction during
aging and age-related degenerative diseases, such as AD. But, it is also evident that the
cholinergic hypothesis can not account for the entirety of the pathophysiology of AD.
Research following has been unable to explain the cause for the loss of these
cholinergic neurons. Moreover, acetylcholine esterase inhibitors used in the treatment of
AD have been mildly effective. Some argue that the efficacy of the drug may be due to
the inability to treat AD early, before significant neuronal degeneration. However, it is
also evident that the loss of cholinergic neurons is not the only pathology present in AD.
There are many important components associated with aging that present severe loss or
dysfunction in age-related diseases (Ball et al., 1997; M. F. Sarter & Bruno, 1994;
Schliebs & Arendt, 2011).
1.2.3 Amyloid Hypothesis
AD is a complex polygenic disease which involves a complexity of anatomical
dysfunctions and molecular pathway disruptions. Three pathological changes are
consistent with AD patients: abnormal Aβ distribution, neurofibrillary tangles due to tau
protein (p-tau) and brain atrophy. The amyloid hypothesis states that AD is, at least in
part, affected by an imbalance in Aβ metabolism, specifically Aβ production and
clearance (Hardy & Selkoe, 2002). Amyloid, in the form of amyloid plaques outside
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cells, and tau tangles, mostly composed of hyper-phosphorylated tau, are one of the first
known anatomical features of late stages of AD. Many patients diagnosed with AD have
extra-neuronal plaques of Aβ due to an underlying disruption of both the amyloid
pathway and non-amyloid pathways which causes cleavage of APP into Aβ, particularly
Aβ42. However, the cause of this disruption in the APP pathway is not yet fully
understood. Moreover, researchers are shifting away from the over simplified assumption
of linear causality introduced by the amyloid hypothesis.
1.2.4 The Inflammatory Hypothesis
Neuroinflammation, caused by the dysregulation of inflammatory cascades in the
brain, is also considered a core pathological component of AD (Streit, Mrak, & Griffin,
2004). Neuroinflammation has been shown in both normal aged patients, and more
severely in age individuals with neurodegenerative changes (Bettcher et al., 2017;
Mosher & Wyss-Coray, 2014; Ownby, 2010; Ransohoff, 2016). It was first described in
the 1980s as a congregation of high levels of astrocytic glial cells in both AD patients and
some aging patients (Beach, Walker, & McGeer, 1989). Later studies indicated a direct
correlation between immune-reactive microglia, using biomarker CD 68, and amyloid or
tau pathology (Arends, Duyckaerts, Rozemuller, Eikelenboom, & Hauw, 2000).
Moreover, post mortem studies indicate that increased markers of microglia were a
consistent feature of AD (Hopperton, Mohammad, Trépanier, Giuliano, & Bazinet, 2018;
Paasila, Davies, Kril, Goldsbury, & Sutherland, 2019). Some researchers hypothesize
that neuroinflammation may perpetuate the formation of pathological markers, such as
amyloid-β plaques and tau tangles, which leads to the neuronal death and dysfunction
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seen in AD, but it is not yet fully understood (Solito & Sastre, 2012; Tuppo & Arias,
2005).
Recent evidence has shown that Aβ plaques are capable of interacting with
microglial and astrocytic receptors that are involved in innate immune response (Minter,
Taylor, & Crack, 2016) . This process involves the secretion of pro-inflammatory
cytokines and has been shown to generate reactive oxygen species (ROS) that drive a
dysregulated immune response which may contributes to neurodegeneration (Cagnin et
al., 2001). In early rodent studies it has been shown that, following acute exposure of
Lipopolysaccharide (LPS), a known proinflammatory virulence factor, there is a
significant decrease in ChAT-positive cells in the BF and an increase in the production of
Aβ and neuroinflammatory markers, including IL-1β, IL-6, and TNF-α (Brugg et al.,
1995; Quan, Sundar, & Weiss, 1994; Willard, Hauss-Wegrzyniak, & Wenk, 1999). Thus,
it has been hypothesized that glial function and cytokine activity play a key role in the
brains immune response to neuronal degeneration.
Microglia are considered the main affector cell of the brain's innate immune
system, and has been implicated in AD and other neurodegenerative diseases. Early
histological studies showed an association between microglial populations and Aβ in AD
patients (Perlmutter, Barron, & Chui, 1990; D. Walker & Lue, 2007). Moreover,
increases in the expression of markers of microglia are widely reported in brains from
patients with AD. Using positron emission tomography (PET) with benzodiazepine
receptor ligand PK-11195, as a marker for microglia, the activation of microglia has been
shown to precede cerebral atrophy in AD patients (Cagnin et al., 2001). This suggests
that microglia activity exacerbates, or possibly triggers, symptoms of AD. Alternatively,
8

studies have suggested that microglia may impair Aβ clearance in the brain (Tejera et al.,
2019). Activated microglia secrete proinflammatory cytokines and chemokines, including
tumor necrosis factor α (TNFα), IL-1β, IL-6, and chemokine C‐C motif ligand (CCL),
which recruit more microglia and glial cells to the effected brain region.
Studies with measuring cytokine activity have also been associated with the onset
of AD. Cerebral spinal fluid (CSF) and blood plasma levels of cytokines reveal a direct
correlation between inflammatory markers, such as TNFα and CCL2 (Diniz et al., 2010;
Tarkowski, Andreasen, Tarkowski, & Blennow, 2003; Westin et al., 2012). This supports
the hypothesis that Aβ production and hyper-phosphorylated tau dysregulate the immune
response system by recruiting microglia and astrocytes which fail to effectively clear the
site; therefore, driving the production of more pro‐inflammatory cytokine and chemokine
production creating a cycle of chronic glial recruitment which may lead to cellular
disturbance and neuronal degeneration seen in AD. Moreover, post-mortem
histopathological and positron emission tomography reveals a co-localization of Aβ and
tau pathology in AD (Fein et al., 2008; Ikonomovic et al., 2008; Teipel et al., 2005). Tau
is a protein involved in the stabilization of microtubules, promotion of neurite outgrowth,
and facilitation of enzyme anchoring and axonal transport of organelles. Interestingly,
studies have demonstrated that both human and mouse microglia can uptake and release
tau seeds, a form of tau capable of inducing tau accumulations, which supports the
hypothesis that microglia may play a direct role in propagation AD by, in part, affecting
the life cycle of seed-competent tau spreading in the brain (Hopp et al., 2018;
Schlachetzki & Hull, 2009; Takeda et al., 2016, 2015).
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Studies which use chronic LPS administration to induce a long-term inflammatory
response in rats can reproduce cellular and behavioral responses similar to patients with
AD, such as increased activation of microglia and astrogliosis, increased tissue levels of
IL-1 and TNF-α, elevated expression of APP , and deficits in memory (HaussWegrzyniak, Dobrzanski, Stoehr, & Wenk, 1998). This supported the hypothesis that,
instead, a potentiated inflammatory response may contribute to the increase in Aβ
production (Raskin, Cummings, Hardy, Schuh, & Dean, 2015). Furthermore, these
studies collectively highlight the key role that inflammatory processes may play in early
AD pathogenesis.
We do know that genetic and molecular changes associated with AD point to the
involvement of immune and inflammatory processes, a complete understanding of the
mechanisms that underlie cell death in Alzheimer’s disease, particularly in primary
targets such as the BF, is not yet known. Recent data clearly show that changes in
immune function can facilitate and trigger the pathophysiology of AD which has
provided a new dimension to the pathogenesis of AD that may lead to novel ways of
diagnosing and treating the disease. Studies have shown that aged individuals are
vulnerable to dysregulation of the immune response leading to chronic inflammation,
considered Inflammaging, but there is still debate as to whether neuroinflammatory
features cause or contribute to age and age-related disease. The two hypothesis remain
possible that inflammation could precede and predict AD or that neuroinflammation is a
component of aging which is exacerbated in age-related diseases.
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1.2.5 Current and Future Pharmaceutical approaches
The population of individuals who develop AD is expected to triple by 2020
generating increased burden on social and health services. This potential economic impact
demonstrates the need to develop more effective therapies capable of identifying and
preventing the progression of AD (Pais et al., 2020). Current pharmaceutical approaches
involve targeting symptoms of AD rather than curing AD. These treatments involve
acetylcholinesterase inhibitors which prevent breakdown of the neurotransmitter ACh to
improve cognition, and a N-methyl D-aspartic acid (NMDA) receptor antagonist, which
have been shown to prevent Aβ toxicity and inflammation associated with AD (Lahiri,
Farlow, Greig, & Sambamurti, 2002; Mangialasche, Solomon, Winblad, Mecocci, &
Kivipelto, 2010; Misra & Medhi, 2013). In AD patients, evidence of only modest
improvements of cognitive symptoms after the application of acetylcholine esterase
(AChE) inhibitors, as well as evidence of the existence of nonresponders, cast doubts on
the cholinergic hypothesis. Moreover, the use of NMDA antagonists only provides some
inflammatory relief to patients suffering AD. To date, there are no biomarkers or
therapeutic mechanisms for identifying or eliminating the progression of Alzheimer’s
disease. Understanding and identifying the earliest pathological signs of AD is vital for
effective early treatment of the disease.
The prevention of the onset or progression of AD at an early stage is critical to
combating this disease. However, it is difficult to determine what constitutes normal agerelated changes from pathological changes which may lead to AD. A central issue in
understanding healthy versus pathological aging leading to neurodegenerative diseases is
clarifying the structural identity of corresponding regions and cell populations
11

compromised during the aging process. The assumption that cholinergic denervation is
the initial step to the development of AD is still in debate. Several studies suggest a
myriad of potential targets disproportionately affected during the aging process including,
immune cells and specific BF neuronal populations, thus rendering them susceptible to
AD related pathologies(Allen, Abogadie, & Brown, 2006; Ball et al., 1997; Jim Fadel &
Frederick-Duus, 2008; Ivana Gritti, Manns, Mainville, & Jones, 2003; Unal, Pare, &
Zaborszky, 2015). Some have suggested that effective pharmacotherapies, administered
in early stages that prevent initial neuronal dysfunction may involve chronic antiinflammatory therapy(S. Hickman, Izzy, Sen, Morsett, & El Khoury, 2018; D. Walker &
Lue, 2007; Wenk et al., 2000). However, identifying whether this is possible and if there
are other key anatomical features which precede and predict the onset of AD are still not
known.
1.3 Aging
Aging remains a central component and the leading risk in the development of
AD. In the early 1970s, scientists noticed a drastic change in brain volume and weight in
aged individuals, starting at around 50 years old, which is exacerbated individuals
previously diagnosed with AD (Chrzanowska & Beben, 1973; Dekaban & Sadowsky,
1978). The loss of volume has been attributed to cortical thinning and neuronal loss in
the hippocampus and BF (Brueggen et al., 2015; Colomb et al., 1996; Fleischman et al.,
2014; Kilimann et al., 2014; Schliebs & Arendt, 2011). Imaging approaches, including
functional magnetic resonance (fMRI) and electroencephalography (EEG), have shown
an age-related decline in neuronal activation during a cognitive related tasks (Rossini et
al., 2007). Cholinergic dysfunction is the most well-known aspect of age-related
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cognitive decline which is seen more drastically in AD patients. It is thought that
neuronal loss in the Basal Forebrain cholinergic system (BFCS) impedes synaptic
processes located in cognitively relevant brain regions such as the cortex and
hippocampus thus leading to cognitive deficits (Teipel et al., 2011). Age-dependent
changes to BF input populations involved in cognition, attention and arousal, such as
orexinergic and dopaminergic populations may also be contributing to age-dependent
dysfunction in the BF. Additionally, changes in inflammation and pro-inflammatory
cytokine release have been linked to aging and AD (Solito & Sastre, 2012; J. Zhang et al.,
2016). Thus, aging has been associated with alterations in cognitive decline,
inflammation, arousal, and homeostatic balance (Kessler, Stanley, Frederick-Duus, &
Fadel, 2011).
1.3.1 Anatomical Components of Aging
The presentation of cognitive decline in aged individuals can range from mild
memory loss to severe dementia, as seen in patients with AD. One component associated
with the development of cognitive deficits seen in aged individuals is the
neurotransmitter ACh. Early studies revealed a loss of biochemical markers for ACh,
including a decrease in AChE and ChAT-positive neurons in aged patients which showed
signs of age-related dementia (Bowen, Smith, White, & Davison, 1976; Elaine K. Perry
et al., 1977). Later studies using cognitive enhancers demonstrated a clear link between
cholinergic transmission and cognition in aged individuals (Riedel & Jolles, 1996).
Conversely, antagonism of cholinergic receptors using the cholinergic antagonist,
scopolamine, produces cognitive impairments (Budzynska et al., 2015; Ebert & Kirch,
1998). Because ACh has an important role in cognitive processes the loss of cholinergic
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neurotransmission has been implicated in cognitive deficits associated with aging, and
severe dementia (H. Ferreira-Vieira et al., 2016; Wilcock, Esiri, Bowen, & Smith, 1982).
Specifically, the cholinergic projections of the BF, have been the most studied and
considered an important component of age-related cognitive decline.
The BF has long been implicated in aging and age-related cognitive decline (Gu,
Wortwein, Yu, & Perez-Polo, 2000). Moreover, the severity of dementia in AD patients
can be attributed to the loss of cholinergic neurons in the BF (Raymond T. Bartus, 2000;
Pappas, Bayley, Bui, Hansen, & Thal, 2000; E. K. Perry et al., 1985). Previous studies
have shown that the BFCS experiences neuronal loss during aging and severe atrophy in
patients diagnosed with AD (Wolf et al., 2014). Thus, aging has been associated with the
loss of function of cholinergic neurons in the basal forebrain due to neuronal loss and
dysregulation of cholinergic neurons left behind. This hypothesis is supported by studies
which show that, in elderly patients, the loss of BF neurons strongly correlates to
cognitive dysfunction in attentional and memory related tasks (M. J. Grothe, Heinsen,
Amaro, Grinberg, & Teipel, 2016; Lammers et al., 2018; Wolf et al., 2014). Thus, studies
today use the ablation of cholinergic neurons using lentiviral vectors, and cholinergic
antagonists in the BF to mimic brain aging and the neurobehavioral deficiencies in AD
(R. T. Bartus, Fleming, & Johnson, 1978; Gu et al., 2000).
Recently, new data has revealed that GABAergic neurons of the BF produce
parallel inputs with cholinergic neurons to affecting regions. This suggests that other
components of the BF and BFCS may play a role in age-related cognitive decline (Ivana
Gritti, Mainville, Mancia, & Jones, 1997a). The input to the BF, or BF afferents, have
also been implicated in age-related changes. Specifically, the cortical system,
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dopaminergic ventral tegmental area (VTA) neurons and orexinergic projections
stemming from the hypothalamus have shown age-related changes (Düzel et al., 2010;
Jim Fadel & Frederick-Duus, 2008; Gielow & Zaborszky, 2017; Laszlo Zaborszky, Pang,
Somogyi, Nadasdy, & Kallo, 1999). However, the exact relationship between these
neuronal populations and age-related cognitive decline has yet to be defined. Moreover,
whether these regions play a primary role in age-related dysfunction is not yet known.
1.3.2 Inflammaging
Inflammatory processes play an important role in the pathogenesis of aging by
maintaining brain homeostasis and immunity. In particular, microglia are involved in
these essential housekeeping functions by surveying the brain for unwanted pathogens
and neuronal debris which can then be ingested and eliminated (Afridi, Lee, & Suk,
2020). Thus, as previously mentioned, microglia are considered a prominent immune cell
of the brain and play a pivotal role in the maintenance of brain homeostasis (Aguzzi,
Barres, & Bennett, 2013). Particularly microglia and astrocytes, are involved in
homeostasis and defense against pathogens during the acute inflammatory phase (S. U.
Kim & De Vellis, 2005). Some microglia survey and clear debris with little to no
inflammation (M2 phenotype), whereas others are considered proinflammatory (M1
phenotype) and can cause high levels of inflammation and cytokine release. The M1
phenotype have been shown to contribute to neurodegeneration (Heppner, Ransohoff, &
Becher, 2015; Martinez & Gordon, 2014; Schmitz, Soreq, Judes Poirier, & Nathan
Spreng, 2020). Moreover, aging has been associated with an increase in the dysfunction
microglial activation and mild loss of neuronal cells involved in these detrimental
functions, such as cognition and homeostasis, in the BF (Schmitz & Nathan Spreng,
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2016). Evidence also reveals a strong correlation between chronic neuroinflammation,
homeostasis and impaired memory, especially in patients with AD(C. M. Duffy,
Butterick, & Nixon, 2019). Specifically, microglial activation and cytokine release are
important factors effected by chronic inflammation which is seen in aged individuals, and
these factors are intensified in age related diseases, such as AD. It is thought that in cases
of chronic inflammation these immune cells can cause neuronal damage if left unchecked
(S. Hickman et al., 2018). Therefore, it has been hypothesized that loss of inputs
originating from the basal forebrain might remove a key check on microglial
inflammation in aged individuals (Schmitz et al., 2020; Schmitz et al., 2018).
Studies measuring cytokine release are uniquely capable of distinguishing
between anti-inflammatory and pro-inflammatory actions of microglia. A study using
aged individuals revealed that microglia become increasingly dysfunctional and release
higher levels of pro-inflammatory cytokines compared to young individuls
(Marschallinger et al., 2020; Solito & Sastre, 2012). Thus, the aging brain is
characterized as having higher levels of pro-inflammatory cytokines, such as TNFα and
IL-1β, and lower levels of anti-inflammatory cytokines indicating a low to mid-grade
level of inflammation (Sparkman & Johnson, 2008). Moreover, microglia in an aged
brains show increased levels of ROS and decreases in phagocytosis which indicates agerelated dysfunction (Koellhoffer, McCullough, & Ritzel, 2017). As previously
mentioned, brains diagnosed with AD have been associated with higher levels of
activation and markers such as Amyloid-β (Hopperton et al., 2018). Thus, microglia,
immune cells which typically play a prominent role in brain health and homeostasis, have
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the potential to have a negative impact on cells during aging, and neurodegenerative
disease.
1.3.3 Homeostatic Imbalance
Aging is linked to changes in physiological homeostatic functions such as
dysregulation of food intake, weight, sleep cycles and metabolism (Chieffi et al., 2017;
Espiritu, 2008; D. Frederick-Duus, Guyton, & Fadel, 2007; Hagar, Macht, Wilson, &
Fadel, 2017). Aged individuals often experience a decrease in food intake followed by
gradual weight loss, a phenomenon known as the “anorexia of aging” (Visvanathan,
2015). Previous studies have shown that age induced homeostatic disturbances leading to
a decrease in food intake and weight loss precede cognitive decline and MCI (Cova et al.,
2016; Danielle Frederick-Duus, 2008; Johnson, Wilkins, & Morris, 2006). Furthermore,
studies have shown that a decrease in body mass may predict the development of MCI
and dementia (Buchman et al., 2005; Johnson et al., 2006). Combined, these studies
indicate a potential age-related mechanism which may precede and predict cognitive
decline.
Alterations in homeostatic processes point towards mechanisms associated with
hypothalamic dysfunction as a potential trigger initiating declining body mass, food
intake, and weight loss associated with aging. The hypothalamus is the regulatory center
for autonomic and endocrine homeostasis, and houses several neuropeptides and neuronal
pathways associated with homeostatic regulation. It is possible that dysregulation of the
neural pathways associated with homeostasis and cognitive function are
disproportionately affected during the aging process making them vulnerable during

17

aging and in age-related diseases. Understanding the behavioral and neuroanatomical
changes that occur in age healthy individuals vs. aged individuals susceptible to MCI and
AD may reveal potential biomarkers for age-related diseases, such as AD.
Previous studies in our lab have linked neuroanatomical changes in orexin
neurons produced by the hypothalamus, with food intake and weight gain (Jim Fadel,
Bubser, & Deutch, 2002; Hagar et al., 2017). Moreover, orexin neurons regulate
physiological and behavioral processes that have major impacts on energy balance and
metabolic state (Inutsuka et al., 2014). Thus, age-related deficits in orexin innervation
may play a key role in the physiological symptoms seen in aging and provide a link
between homeostatic dysfunction and the onset of AD. Thus, age-related decline of the
orexin system has been a key factor in the aging process (Danielle Frederick-Duus,
2008; Kessler et al., 2011). Research has shown an age-related decline in orexin
concentration and neuropeptides which parallels physiological changes such as food
intake and sleep (Desarnaud et al., 2004; Martone et al., 2013; Matsumura et al., 2002;
Porkka-Heiskanen, Alanko, Kalinchuk, Heiskanen, & Stenberg, 2004). Moreover, agerelated morphological changes of orexin neuron terminals points to an underlying
dysfunction in orexin signaling during aging (J. H. Zhang, Sampogna, Morales, & Chase,
2005). Further studies analyzing receptor dysfunction and overall loss of orexin
signaling during aging demonstrate a link to cognitive decline (Terao, Apte-Deshpande,
Morairty, Freund, & Kilduff, 2002; J. H. Zhang, Sampogna, Morales, & Chase, 2002). In
total, age-related dysfunctional orexin signaling in orexin may underlie age-related
change in homeostatic and cognitive functions. Further studies analyzing the relationship
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between homeostatic maintenance and orexin are still necessary in understanding the role
of homeostatic dysfunction in aging and age-related neurodegenerative diseases.
1.3.5 Summary
Aging is associated with changes in neuroanatomical pathways associated with
cognitive decline, inflammation and homeostatic imbalance. It is important to note that
the reason some individuals may experience normal mild cognitive decline without
developing severe cognitive impairments is not yet understood. Although the BF and
cholinergic neurons of the BF have been expansively studied and implicated in cognitive
aging, the BF is a complex structure and it is still unclear as to why some individuals
experience more BFCS neuronal loss and to what extend age-associated cognitive decline
can be related to BFCS in normal aging. (Ivana Gritti et al., 1997a, 2003). Moreover,
treatments associated with increasing cholinergic transmission, such as AChE inhibitors,
have not been successful in reversing cognitive deficits related to normal aging or AD.
This suggests that there may be other components in the BF that are vulnerable to
dysfunction in aging, or perhaps that neuronal populations communicating with the BF
could be effecting the cognitive processes which are lost during aging and more severally
in age-related diseases such as AD.
The role of inflammatory processes in aging is evident; however, there is still
ongoing debate as to whether inflammation precedes or follows age-related dysregulation
in the brain. The role of glial cell activation in the BF during the aging process has been
sparsely researched and further insight into the potential relationship between aging,
homeostatic neuronal pathways and microglial dysfunction is necessary. Microglia
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contribute to overall brain homeostasis, and thus there could be pivotal to distinguishing
unhealthy aging from healthy aging. Furthermore, our lab has shown that orexin plays an
important role in homeostatic balance in aged animals and is capable of rescuing
cognitive function by activating neurons in key cognitive areas such as the basal
forebrain and prefrontal cortex (Calva & Fadel, 2020; Calva, Fayyaz, & Fadel, 2018,
2020). This suggests age-related orexin loss may contribute to key symptoms associated
with aging including cognitive decline, inflammation, and homeostatic imbalance (J. R.
Fadel, Jolivalt, & Reagan, 2013; Danielle Frederick-Duus, 2008; Porkka-Heiskanen et al.,
2004). In this study, we hypothesize that age-related dysfunctional changes in neuronal
groups associated with homeostatic regulation in BF may contribute to the vulnerability
of these neurons during aging.
1.4 Basal Forebrain
Our understanding of the BF has shown significant advances in regards to the
implications of its anatomical pathways. The BF is a heterogeneous set of subcortical
nuclei which include the substantia innominata, medial septum, ventral pallidum, nucleus
basalis and diagonal/vertical bands of broca which are located below the striatum and
behind the frontal lobe (Laszlo Zaborszky, van den Pol, & Gyengesi, 2012). The BF
nuclei have a heterogeneous set of neurons which have variable physiological properties
and functions which represent their specific repertoire of afferent inputs (Hangya,
Ranade, Lorenc, & Kepecs, 2015). The BF has been implicated in cognitive functions
including attention, motivation, and arousal. Additionally, the BF integrates the signals
from these areas by converging several signals which contribute to the output, or efferent,
neurotransmitter release to areas of the brain including the hippocampus, amygdala,
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Prefrontal Cortex (PFC), and Ventral Tegmental area (VTA). Some of these projections
are considered bilateral to maintain bidirectional communication necessary for proper
regulation. Thus, the BF has been described as a weigh station for several signaling
pathways.
The BF regulates these functions through several neuronal populations including
cholinergic, glutamatergic, GABAergic efferent neurons. The local cell populations,
including the microglial cells and GABAergic interneurons, also play a pivotal role in
regulating important signals and maintaining homeostatic balance. The anatomical
complexity of the basal forebrain creates a challenge in understanding the functional of
the BF, as well as the information processing characteristics which contribute to disease
states. For this reason, research has only mildly elucidated the intricacies and
complexities of the BF.
1.4.1 Acetylcholine and the Basal Forebrain Cholinergic System
The BFCS, a set of BF outputs which release ACh, plays an important role in
cognitive functions including critical physiological processes, such as attention, memory,
wakefulness and sleep, and decision-making (H. Ferreira-Vieira et al., 2016). The BFCS
is located in the nucleus basalis magnocellularis (nBM), ventral pallidum/substantia
innominata (VP/SI), diagnol bands of broca, and medial septum, first defined by as the
Ch4 subgroup using Mesulam’s nomenclature (M. ‐Marsel Mesulam, Mufson, Levey, &
Wainer, 1983; M. Marsel Mesulam & Mufson, 1984). As mentioned previously, the
BFCS has been the most widely studied set of BF efferent neurons and has been shown to
be particularly vulnerable to dysfunction and degeneration in aged humans and, more
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dramatically, in diseases such as Alzheimer's disease. Experiments performed using tract
tracers and immunohistochemistry (IHC), have shown that the BFCS mainly sends
outputs to the hippocampal formation, , the cortex, and the limbic system (Clark &
Editors, n.d.; Gielow & Zaborszky, 2017). Although it was first hypothesized that these
outputs were diffuse, it is now accepted that the BFCS provides topographically and
functionally organized efferent to these limbic system and cortical areas of the brain, and
that its wide spread projections provide a central modulating neurotransmitter system
which is implicated in diverse behavioral processes (Bloem et al., 2014; M. M.
Mesulam, 1996; Laszlo Zaborszky et al., 2015).
To study the functional significance of these outputs, injuries were introduced to
BFCS using immunotoxins in rodent and non-primate models which led to attentional
deficits in several animal models including monkeys and rats (Bucci, Holland, &
Gallagher, 1998; Irle & Markowitsch, 1987; Voytko, 1996; Voytko et al., 1994). Early
lesioning studies confirming cholinergic loss using ChAT activity demonstrated
behavioral deficits following the loss of cholinergic neurons from the BF (Dekker,
Connor, & Thal, 1991). Additionally, a more specific infusion of IgG-saporin, an
immunotoxin which specifically destroys cholinergic neurons, into the BF produced
cognitive deficits in several attention/cognitive tasks (Russchen, Amaral, & Price, 1985;
Torres et al., 1994). The BFCS projects diffusely across the cortical mantle, where the
functional topography is yet to be fully understood. Evidence has indicated that BF
cholinergic neurons synapsing on glutamatergic neurons in the cortex and thalamus are
involved in modulating the response of these neurons (McCormick, 1993). When
cholinergic immunotoxins, target the low affinity form of the NGF receptor preferentially
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expressed on cholinergic neurons, are applied to hippocampal regions which receive
many cholinergic projections, memory deficits were shown, whereas cholinergic
stimulation increased hippocampal memory formation. Thus, the BFCS expresses distinct
functional connections, where outputs synapsing at the cortex modulate attentional and
awareness, but ACh neurons synapsing at the hippocampus affect learning and memory
(Ballinger, Ananth, Talmage, & Role, 2016; Bloem et al., 2014).
Post mortem studies of patients diagnosed with AD illustrate a significant
decrease in cholinergic neurons, specifically in the nucleus basalis (Arendt, Bigl,
Tennstedt, & Arendt, 1985; Hedreen, Struble, Whitehouse, & Price, 1984; Whitehouse et
al., 1982). Early studies using scopolamine, a muscarinic receptor antagonist, showed a
similar pattern of cognitive deficits as to what was observed in elderly individuals
(Drachman & Leavitt, 1974; Ebert & Kirch, 1998). Thus, blocking a receptor whose
modulator is acetylcholine causes similar attributes in young individuals as seen in
elderly, such as attentional and memory deficits. This, and many following studies, led to
the understanding that age-related cognitive deficits seen in elderly and AD patients
could be caused by a loss in cholinergic function. Thus, the deficits could be reduced
using the anticholinesterase, physostigimine, which was first shown in aged monkeys (R.
T. Bartus et al., 1978; Raymond T. Bartus, 1979). Today, most treatments used to
alleviate cognitive symptoms of AD are acetylcholine esterase inhibitors, which acts to
prevent the enzyme, which normally breaks down Ach at the synapse, from degrading
Ach (Pepeu, Giovannini, & Bracco, 2013). However, these treatments are only mildly
effective because there are relatively few cholinergic neurons for the drug to act on, and
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there is still very little understood about the pathways which contribute to cholinergic
output.
1.4.2 GABA
While extensive research surrounding hypotheses about the cognitive and
attentional functions mediated by the BFCS have been substantiated in recent years,
knowledge about the behavioral and functional contributions of the large population of
GABAergic neurons has remained scarce. Of particular interest are the GABAergic
efferent neurons which have been shown to colocalize with the BF cholinergic neurons.
Immunohistochemical studies, using ChAT and calcium-binding protein Parvalbumin
(PV), have shown that GABAergic neurons outnumber cholinergic neurons 2:1, it is
predicted that a similar number of GABAergic neurons and cholinergic neurons (1:1)
form parallel projections while other GABAergic neurons are considered part of the local
GABAergic interneuron population (Ivana Gritti, Mainville, & Jones, 1993; Kiss, Patel,
Baimbridge, & Freund, 1990; M. Sarter & Bruno, 2002). It is important to note that in the
BF, 90% of GABAergic (immunostained via GAD+) neurons are also PV+, and that
these studies reflect staining with PV as a GABAergic marker (Ivana Gritti et al., 2003).
Some studies suggest that BF interneurons (PV+) play a significant role in cortical
response that perhaps contribute to attentional processes and executive functions by
interacting with projecting GABAergic and cholinergic neurons (Freund & Meskenaite,
1992a; T. Kim et al., 2015). For example, the BF afferents from the PFC have been
shown to target GABAergic neurons, and it is predicted that these neurons contribute to
regulation of efferent neurons (Ronald P.A. Gaykema, Van Weeghel, Hersh, & Luiten,
1991; Ronald P.A. Gaykema & Zaborszky, 1997).
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It has been well established that the BF corticopetal nuclei contain BF cholinergic
(ChAT+) and GABAergic (PV+) neurons which project cortically (Ferguson & Gao,
2018; Hooly Moore, Sarter, & Bruno, 1995; M. Sarter & Bruno, 2002; Laszlo Zaborszky
et al., 1999). The stimulation of the BF GABA corticopetal projections inhibits the
excitability of cortical interneurons, which demonstrates a potent cortical disinhibition
(M. Sarter & Bruno, 2002; M. F. Sarter & Bruno, 1994). Furthermore, studies have
shown that large PV+ neurons of the BF that project cortically synapse on pyramidal cells
of the cortex (Ivana Gritti et al., 1993, 1997a, 2003). These PV neurons from the BF play
a significant role in regulating the glutamatergic pyramidal and GABAergic PV
interneuron activity in the cortex which contribute to the balance of excitatory/inhibitory
activity (feedforward/feedback inhibition) that drives behavioral responses such as
planning, decision-making, attention, and working memory (Ferguson & Gao, 2018;
Freund & Meskenaite, 1992b; H. Hu, Gan, & Jonas, 2014; Packer & Yuste, 2011).
Although the BF GABAergic neurons within the corticoseptal pathway have been
studied, little is known about how the local GABAergic interneurons may regulate other
pathways and behaviors. Moreover, although there is debate as to whether the
GABAergic neurons of the BF are compromised during AD, their role in aging and these
age-related diseases has not yet been elucidated (Hä et al., n.d.; M. Sarter & Bruno,
2002).
1.4.3 Glutamate
The BF glutamatergic neurons are the least understood of the three neuronal
phenotypes in the BF. Immunohistochemical staining of glutamatergic neurons, using
vesicular glutamate transporter marker (vGLUT) and phosphate-activated glutaminase
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(PAG), revealed that glutamatergic neurons are a separate phenotype form GABAergic
and, in some cases, cholinergic neurons (Fremeau, Voglmaier, Seal, & Edwards, 2004;
Ivana Gritti et al., 1993; Herzog et al., 2001; Manns, Mainville, & Jones, 2001). Studies
have revealed that glutamatergic afferents of the BF originate from the cortex, amygdala,
and telencephalic areas including the VTA (Ronald P.A. Gaykema et al., 1991; Haring &
Wang, 1986; L. Zaborszky, Gaykema, Swanson, & Cullinan, 1997). Microdialysis
studies, which administered amphetamine, which acts primarily on NMDA and
dopaminergic receptors, to the SI/NBM of the BF demonstrated that excitation of the
glutamate receptors in the BF can excite cholinergic neurons to release Ach in the PFC
(Lamour, Dutar, Rascol, & Jobert, 1986). Moreover, stimulation NMDA in the BF
stimulated cortical Ach release in response to a food-paired behavioral stimulus (Arnold,
Fadel, Sarter, & Bruno, 2001; Jim Fadel, Sarter, & Bruno, 2001). This indicates a
potential role for BF glutamate in attentional and cognitive function. Later studies
demonstrated a role for these cholinergic and glutamatergic transmission in top-down
regulation, the regulation of attentional functions of environmental stimuli, in the PFC
(Nelson, Sarter, & Bruno, 2005).
1.4.4 Microglia
Microglia are prominently known for their role in the innate immune system
which guards against neuronal injury and infection. While it is well understood that
microglia play a central role in detecting and clearing pathogens and unwanted debris in
the brain, there is little understanding of different functions microglia may have in
different regions of the brain. Recent studies have found that neuronal signaling exerts a
significant impact on proinflammatory processes of glial cells. In particular, ACh release
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has demonstrated anti-inflammatory actions on microglia, termed the cholinergic antiinflammatory pathway (Pavlov & Tracey, 2005). It has also been hypothesized that
cholinergic neurons of the BF can regulate microglial activity in the brain through
cholinergic modulation (Gamage et al., 2020). This mechanism for neuronal-glial
interaction has been demonstrated in hippocampal microglia in which nicotinic
acetylcholine receptor α7 subunit (nAChRα7) agonists suppresses glial TNFα release (H.
Wang et al., 2003). Thus, a role for neuronal-microglial communication is emerging, and
it is clear is clear that ACh is necessary to maintain microglial homeostasis. However, the
exact mechanism for neuronal-glial interactions are not known and whether other
phenotypes of neurons may play similar or opposing roles has yet to be investigated.
Microglia have been known to impact the BF neuronal environment during aging
and age-related diseases. A loss of BFCS neurons, which have been shown to occur in
aging and AD, results in microglial reactivity to Aβ and Tau protein which may
contributes to uncontrolled inflammation and unnecessary neuronal death (Schmitz et al.,
2020). In aging humans, significant levels of microglial inflammation, measured via
cytokine release, have been demonstrated (Chung et al., 2009; Rea et al., 2018; Schliebs
& Arendt, 2011). are In a rat Aβ42 lesion model, BF cholinergic neurons in the SI/NBM
showed significant degeneration and high levels of microglial activation (Nyakas, Granic,
Halmy, Banerjee, & Luiten, 2010). Moreover, it is still not fully understood as to how the
loss of BF cholinergic tone to the forebrain, which occurs in aging and age-related
diseases such as AD, may affect microglial in the BF and major BF efferent targets,
such as the hippocampus and cortex.
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1.4.5 Summary
The BF several neuronal phenotypes including cholinergic, glutamatergic, and
GABAergic neurons, as well as glial cells. The BF consists of efferent cholinergic and
glutamatergic component that serves to amplify sensory input and promote attentional
and cognitive processing, and a GABAergic component that projects cortically mediating
executive functions which require a flexible modulation. Meanwhile, GABAergic
interneurons of the BF are involved in the regulating bilateral feedback from several
pathways. Collectively the BF integrates circuits involved in sensory, cognitive,
attentional and decision making processes in order to provide a context-adequate
behavioral response. Additionally, it has been shown to be susceptible to aging and is
thought to play a major role in cognitive and attentional deficits seen in AD patients. It is
clear that our understanding of the functions of the BF will remain inadequate in the
absence of evidence concerning the role of its GABAergic and other noncholinergic
components. Moreover, our understanding of the pathways in which the BF integrates
may provide a clue as to what components of the BF are vulnerable to dysfunction in
aging and age-related disease.
1.5 Inputs to the Basal Forebrain
The BF plays a significant role in the information processing and integrating
several signals from several neuronal types in the brain. Importantly, the BF receives
several inputs from various brain regions including the insular cortex (IC), medial
prefrontal cortex (PFC), lateral hypothalamus (LH), VTA, nucleus accumbens (NAc) and
amygdala. These projections make contact with several populations in the BF including
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BFCS, glutamatergic neurons, GABAergic neurons and microglia mentioned previously.
We know the loss of BF neurons can effect neural networks which rely on BF input to
provide necessary communication attributed to the cognitive and homeostatic balance
necessary for proper function. It is also possible that the dysfunctional signaling
contacting the local BF neurons may contribute in some way to neuronal dysregulation
and degeneration. Recent evidence has documented details of the afferent networks of the
basal forebrain (R. P.A. Gaykema, Gaal, Trader, Hersh, & Luiten, 1991; Heimer &
Alheid, 1991; L. Zaborszky, Cullinan, & Braun, 1991). These regions which send
afferent inputs to the BF may be involved in the circuits which seem to manifest the
neuronal dysfunction and degeneration in age-related diseases, such as AD (R. Hu, Jin,
He, Xu, & Hu, 2016; M. Sarter, Bruno, & Turchi, n.d.). For example, studies using in
vivo microdialysis to measure cholinergic release in several brain regions following
operant tasks have revealed a role for cortical neurons associated with the BFCS to
contribute to attentional processing associated with the cognitive symptoms of AD which
show mild cognitive decline during the aging process (J. Fadel & Burk, 2010a; Hasselmo
& Sarter, 2011; Kessler et al., 2011; Holly Moore, Sarter, & Bruno, 1992; M. Sarter,
Givens, & Bruno, 2001). (Auerbach & Segal, 1996; Blitzer, Gil, & Landau, 1990;
Hasselmo & Sarter, 2011). This suggests that cholinergic dysfunction strongly correlates
to a dysfunction in neuronal inputs associated with cognitive function. However, it is still
not known how these regions are effected during normal age relate changes and there is
still much to learn about afferent neuronal populations which make contacts with the
BFCS and local cell populations.
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1.5.1 The Prefrontal Cortex
Several tract-tracing studies using anterograde tracers have suggested that the
cortex sends a significant portion of projections to the basal forebrain (Haring & Wang,
1986; M.-M. Mesulam & Mufson, 1981). Tract tracing studies paired with cholinergic
immunohistochemistry have revealed that PFC and insular cortex (IC) send highly
organized bilateral projections between cortices and the BFCS (Chaves-Coira, RodrigoAngulo, & Nuñez, 2018; Ronald P.A. Gaykema et al., 1991). Later studies found that the
boutons of the neurons from the PFC were both excitatory, glutamatergic neurons, and
inhibitory, GABAergic neurons (L. Zaborszky et al., 1997). Recent findings have shown
that the presence of specific neuronal networks between the BF and cortical regions, such
as the PFC and IC, that may play different roles in the control of cortical activity
(Chaves-Coira, Martín-Cortecero, Nuñez, & Rodrigo-Angulo, 2018).
The medial PFC sends important GABAergic and glutamatergic projections to the
BF, and is thought to be central to processing and cognition, including decision-making
and memory. The medial PFC has two sub regions, the prelimbic cortex (PLC) located in
the most medial portion of the frontal cortex under the cingulate, and the infralimbic
cortex (ILC) located directly below the PLC. The ILC and PLC have both been shown to
send major connections to the BF (Vertes, 2003; L. Zaborszky et al., 1997; Laszlo
Zaborszky et al., 2015). Studies using appetitive lever press rewards showed an increased
activation of PFC and ILC excitatory neurons which indicated a role for both regions in
homeostatic response (Burgos-robles, Bravo-rivera, & Quirk, 2013). The PLC and ILC
bilateral projections are also thought to play an important role in fear and memory
extinction by sending important projections to the BFCS which end in the amygdala and
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hippocampus (Knox, 2016; Knox & Keller, 2016). Perhaps, the most interesting
hypothesis involves the significance of the BF in mediating both fear/extinction and
reward memories to be sent to the hippocampus and amygdala. Thus, findings have
revealed specific areas of the BF project bilaterally to the PFC, however, their role in
aging and age-related dysfunction has yet to elucidate.
1.5.2 Insular Cortex
The IC, also known as the insular lobe, is a portion of the cerebral cortex beneath
the lateral sulcus and located in the center of both cerebral hemispheres of the brain. It is
divided into three regions which are adjacent to each other, the agranular, dysgranular
and granular layers (Augustine, 1996). The IC was first proposed to have a role in taste
and feeding behaviors, including cue potentiated feeding (Augustine, 1985; S. Cole,
Hobin, & Petrovich, 2015; Sindy Cole, Keefer, Anderson, & Petrovich, 2020). Early
analysis of neuronal activity in monkeys concluded that only 10% of the neurons in the
IC are related to taste, 20% are related to sensory or motor responses, but most neurons in
the IC were considered a mystery. We now know that the IC sends projections to the
cortex, amygdala, limbic system, thalamus, and basal ganglia, and receives projections
from these same regions (Flynn, Benson, & Ardila, 1999; M. Nagai, Kishi, & Kato, 2007;
Michiaki Nagai, Scheper, Lenarz, & Förster, 2021). Following research has shown that
the IC is activated in response to several stimuli involved in maintaining the homeostatic
balance of one’s state of being, these stimuli include hunger, thirst, itch, touch, body
temperature, heartbeat, gastric, and bladder signals (A. D. Craig, 2003, 2013; A. D. B.
Craig, 2011; Teipel et al., 2018). Moreover, studies have shown that after chewing,
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salivating, or swallowing, there are changes in insular cortex signaling, (Flynn et al.,
1999).
There has been some evidence that illustrates several neurochemical changes are
occurring in the IC during interoceptive awareness. Our lab has shown that following
food-paired stimuli the IC increased efflux of several neurotransmitters including GABA,
glutamate, and ACh and that these signals are reduced in aged models (Hagar et al.,
2017). Moreover, the BFCS has been known to send cholinergic and GABAergic
projections to the IC which, in response to homeostatic cues, are activated (Afif &
Mertens, 2010; Evrard, 2019; Rodríguez-García, María, & Miranda, 2016; M. Sarter &
Bruno, 2002). Given the bidirectional relationship between the IC and BF, in which the
IC has been shown to send mainly glutamatergic projections to the BFCS and
GABAergic efferent and local neurons, it has been hypothesized that the IC is responsible
for processing several signals to sense of the physiological condition of the body, named
interception (A. D. Craig, 2003, 2013; A. D. B. Craig, 2011). Thus, this circuitry may be
important for biasing attentional resources toward external stimuli related to underlying
physiological status which becomes deficient with age. However these age-related
changes are still not well understood, and it is still not known how these changes may
affect the BF during aging.
1.5.3 Nucleus Accumbens
The NAc is a heterogeneous region, located in the rostral and ventral forebrain,
and is split into two primary segments: a medial shell and lateral core. The NAc is
thought to receive a significant portion of the inputs from the basal ganglia, but also
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receives inputs from glutamatergic neurons of the amygdala, hippocampus, thalamus, and
PFC (H. J. Groenewegen, der Zee, te Kortschot, & Witter, 1987). As a whole, the NAc is
a significant player in controlling the biological drives necessary for survival including
feeding, reproduction, and reward/motivation (Boswell & Kober, 2016; Pratt, Will,
Kelley, & Baldo, n.d.; Rebec, Grabner, Johnson, Pierce, & Bardo, 1996). However, the
shell and core subregions receive different inputs which suggests that they may serve
distinct behavioral functions (Salgado & Kaplitt, 2015; Zahm, 2000). This has been
supported in tract tracing studies in which the afferents entering the shell, including the
piriform and infralimbic cortex, differ from the afferents entering the core, including the
insular and prelimbic cortex (Brog, Salyapongse, Deutch, & Zahm, 1993). Glutamatergic
and dopaminergic inputs into the shell play a role in reinstatement drug seeking behavior,
this has been implicated in cortical shell afferents and VTA afferents (Bossert et al.,
2012; Henk J. Groenewegen, Wright, Beijer, & Voorn, 1999; Sesack, Deutch, Roth, &
Bunney, 1989). However, inputs into the core are involved in the cognitive processing of
functions related to reward and reinforcement via afferent regions including the lateral
hypothalamus, temporal lobe, and brain stem (Brog et al., 1993).
The main efferent neurons from the NAc are medium spiny neurons (>90%) that
send GABAergic projections to various areas of the mesencephalon and basal ganglia.
Lesioning studies have shown that lesions of the nucleus accumbens result in a depletion
of GABAergic activation of the BF (Záborsky & Cullinan, 1992; L. Záborszky, Carlsen,
Brashear, & Heimer, 1986). More recent work has shown that the BFCS is innervated by
GABAergic afferents originating largely in the NAc (M. Sarter, Bruno, & Turchi, 1999).
Furthermore, other studies using dopaminergic receptor antagonist, resulted in
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attenuation of GABAergic output to the BF and support the hypothesis that NAc
GABAergic neurons can control the excitability of basal forebrain cholinergic neurons
(M. Sarter et al., 1999). In response, the BF sends inhibitory outputs to the VTA which
makes dopaminergic contacts on the NAc to form a bilateral disinhibitory circuit (J.
Wang et al., 2021). Thus, the BF, VTA and NAc form an intimate pathway which is
highly involved in motivational recruitment of attention by homeostasis-associated cues
(Tashakori-Sabzevar & Ward, 2018). However, this relationship is not yet fully
understood as it relates to aging and age-related diseases.
1.5.4 VTA
The VTA is located in the midline of the lower midbrain next to the substantia
nigra, and contains glutamatergic, GABAergic, and dopaminergic neurons. Although the
VTA contains many types of neurons, it is characterized by its large population of
dopaminergic neurons (Morales & Margolis, 2017). The VTA plays a significant role in
decision making, working memory, stimulus salience and positive/negative reinforcement
(Adcock, Thangavel, Whitfield-Gabrieli, Knutson, & Gabrieli, 2006; Berridge, 2007;
Bromberg-Martin, Matsumoto, & Hikosaka, 2010; Salamone & Correa, 2012). The
lateral hypothalamus, and dorsal raphe are the largest sources of inputs to the VTA, but
the VTA is also known to make microcircuits with nearly all brain regions it projects too
(Beier et al., 2015; Watabe-Uchida, Zhu, Ogawa, Vamanrao, & Uchida, 2012).
The dopaminergic neurons of the VTA project through two distinct pathways, the
mesocortical pathway and the mesolimbic pathway. The mesocortical pathway projects to
several cortices including the PFC, cingulate cortex, orbital cortex, sensory cortex, and
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motor cortex, and contributes to motivation and executive function. Meanwhile, the
mesolimbic cortex projects to the NAc, and amygdala and is associated with reward and
reinforcement. Although most of these functions are attributed to the dopaminergic
system, it is thought that certain populations of GABAergic and glutamatergic output
neurons can also play a role in motivational and reward behavior (Qi et al., 2016;
Stamatakis et al., 2013; Van Zessen, Phillips, Budygin, & Stuber, 2012). One such area
that may receive projections from several neuronal cell types of the VTA is the BF. It is
hypothesized that the BF plays a key role in mediating inputs from the brainstem,
including the VTA and substantia nigra and that dopaminergic, glutamatergic and
GABAergic of the VTA project to the BF, but it is not known whether all of these
projections synapse on BF cholinergic neurons (L. Zaborszky et al., 1997). Recent
studies have shown that the BF cholinergic neurons projecting to the PFC receive inputs
from the VTA. (Gielow & Zaborszky, 2017). Additionally, there is some evidence
indicating these connections may play a role in reward uncertainty, value, and
punishment decision making, but further investigation into the behavioral role of these
inputs to BF neurons is needed to uncover the specific behavioral components of these
pathways (Monosov, Leopold, & Hikosaka, 2015).
1.5.5 The Lateral Hypothalamus and the Orexinergic System
As mentioned previously, the BF is regulated by a variety of inputs, including the
LH, whose cell bodies are located within the postero-lateral hypothalamus (Villano et al.,
2017). Early lesioning studies demonstrated that the ablation of LH neurons would
inhibit feeding and drinking behaviors (Anand & Brobeck, 1951; Morrison & Mayer,
1957). Thus, the LH is considered to be the feeding center of the brain and plays an
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important role in homeostatic physiology and behavior (Stuber & Wise, 2016). The LH
contains a plethora of neurotransmitters and neuropeptides, including glutamate, GABA,
melanin concentrating hormone, and orexin, cell populations that are important for
regulating feeding and reward. It is worth noting that some of these cells groups regulate
feeding within the same neurons. For example, studies using immunohistochemistry have
shown that glutamate containing neurons also contain orexin neuropeptides (Rosin,
Weston, Sevigny, Stornetta, & Guyenet, 2003).
In the late 1990’s, two separate research groups, Lecea and Sakurai,
simultaneously discovered the neuropeptide orexin, also termed hypocretin (L. De Lecea
et al., 1998; Sakurai et al., 1998). They found that these orexin neurons exclusively
originate from the LH and supported a role for orexin in promoting feeding behavior and
energy homeostasis (Sakurai et al., 1998). Orexin neuropeptides, including orexin A
(OXA) and orexin B (OXB), bind to two G protein-coupled receptors, the orexin 1
receptor (OXR1) binds OXA; whereas the orexin 2 receptor (OXR2) binds OxA and OxB
with roughly equal affinity (Ammoun et al., 2003; Scammel & Winrow, 2011; Smart &
Jerman, 2002; Thompson, Xhaard, Sakurai, Rainero, & Kukkonen, 2014). The orexin
neurons project diffusely across the mammalian brain to areas including the PFC, VTA,
BF, NAc, and other hypothalamic regions (Eggermann et al., 2001; Kukkonen,
Holmqvist, Ammoun, & Åkerman, 2002; Peyron et al., 1998). Due to the extensive
terminal fields of the orexin neurons, signaling is well positioned to integrate multiple
physiological processes such as arousal, energy homeostasis, reward seeking, autonomic
function, and cognition. This wide variety of connections of orexin projecting neurons
demonstrates a wide range of cognitive, behavioral function which have collectively
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earned their description as “physiological integrators” (Luis De Lecea, Sutcliffe, & Fabre,
2002; J. R. Fadel et al., 2013).
Orexins provide substantial innervation to nuclei that are the source of diffuse
neuromodulatory transmitters, including dopamine neurons of the ventral tegmental area,
cholinergic neurons of the basal forebrain, and cholinergic and glutamatergic neurons of
the PFC (Calva et al., 2018; Espana, Baldo, Kelley, & Berridge, 2001; C. Fadel et al.,
2005; Jim Fadel et al., 2002). Our lab has shown that orexin innervation of the VTA
contributes to the reported changes in motivated behaviors related to food and drug
reward (Morgan, Harrod, Lacy, Stanley, & Fadel, 2013). Recent research has also shown
that orexin neurons promote arousal, cognition, and attention through their projections to
the BFCS and PFC. Our lab has demonstrated that orexin administration results in an
increase in acetylcholine and glutamate from the PFC (Calva & Fadel, 2020; Calva et al.,
2018; J. Fadel, Pasumarthi, & Reznikov, 2005). We hypothesize that the release orexin in
the PFC and BF activates cortical neuronal activity is vital to attentional and cognitive
processing, as well as maintenance of energy homeostasis. We further devise that these
afferent pathways are vulnerable during aging. Previous studies in our lab and others
have shown that aged animals are unresponsive to orexin and observe a reduction in
orexin neurons innervating cholinergic neurons of the LH (>40%) and BF (Danielle
Frederick-Duus, 2008; Kessler et al., 2011). These alterations in orexin regulation may
contribute to the age-related dysfunctions in arousal, attention, and cognition seen in aged
individuals, and may represent a highly vulnerable set of neurons susceptible to agerelated diseases, such as AD.
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1.6 Hypothesis
Age-related BF dysfunction may reflect diminished afferent regulation as well as
an altered local environment. We have previously shown reduced orexin/hypocretin
innervation of BF in aging, a phenomenon that may link afferent dysfunction with altered
microglial homeostasis. There is little research examining these relationships involving
afferent neuronal and glial cell populations in the BF as it relates to aging. The purpose of
this study is to compare specific neuronal and glial populations to identify anatomical
factors susceptible to age-related homeostatic dysfunction in the BF using behavioral
tasks, IHC, and enzyme-linked immunosorbent assay (ELISA). I hypothesize that aging
contributes to dysfunctional changes in neuronal and microglial activation in the BF. I
aim to identify age-related changes in afferent regulation, neuronal activation, and
microglial morphology following changes in homeostatically relevant stimuli.

Figure 1.1 Overall BF afferent circuitry investigated. A schematic summary of
inputs to the BF involved in age-related processing of salient stimuli.
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1.6.1 Specific Aims
Aim 1: To identify age-related changes in neuronal activation of basal forebrain afferent
population.
Aim 2: To evaluate age-related changes in activation of specific neuronal populations in
the BF.
Aim 3: Investigate the role of orexin-microglial interactions as it relates to age-related BF
homeostatic function.
Together, these studies will reveal targets of age-related dysfunction which may
play a role in age associated MCI that may be exacerbated during age-related diseases
such as Alzheimer’s disease.
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CHAPTER 2. GENERAL METHODS
2.1 Rationale for animal care and use
All Animal care and use procedures were carried out in accordance with protocols
written under the guidelines of the National Institute of Health Guide for the Care and
Use of Laboratory Animals approved by Institutional Animal Care and Use Committee at
the University of South Carolina School of Medicine (Animal Use Protocols #). Every
effort was made to minimize the number of animals used and their suffering.
2.2 Subjects, Handling, and Habituation
Male, F344/Brown Norway F1 hybrid rats (250-300g; National Institute of Aging
Colony, Baltimore, MD, USA) were initially pair-housed on a 12-h light/dark cycle
(lights on at 07:00 h) and fed with standard laboratory chow and water freely available.
Young rats were approximately 3-4 months and aged rats were approximately 26-28
months upon arrival to the animal facility. The FBN/F1 hybrid rat strain has been
continuously used by our laboratory and other labs conducting aging studies due to their
reduced susceptibility to several non-neurological age-related complications, including
intraperitoneal tumors which are frequently observed in other strains (Lipman, Chrisp,
Hazzard, & Bronson, 1996; Van Der Staay & Blokland, 1996). Therefore, the FBN/F1
hybrid strain was used to compare the effects of cognition in a food-paired stimulus test
to determine the neuronal activation dysregulation during aging. Furthermore, previous
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lab work has used this strain of rat to study orexin-aging connections (Calva & Fadel,
2020; Calva et al., 2018; D. Frederick-Duus et al., 2007; Hagar et al., 2017; Kessler et al.,
2011). All animals were handled daily during the first week while being housed in an
environmentally controlled animal facility and kept on a 12:12 light: dark cycle with
lights on at 07:00 h. Animals were given standard rat chow, ad libitum. During the
second week, animals were separated and food intake of freely available standard chow
was measured. On the third week, animals were given a food restricted diet that consisted
of 80% of their standard diet. Several measures were taken to minimize animal suffering
during experimentation, including careful monitoring of animal health during habituation,
monitoring anesthetic state during surgery, administration of analgesics to ease postoperative pain.
2.3 Stereotaxic Surgery
Stereotaxic surgery is used for site-specific targeting of specific brain regions
using 3 sets of coordinates generated in relation to bregma, the intersection of the coronal
and sagittal sutures of the skull. To begin, all animals were anesthetized using isoflurane
(Piramal Critical Care Inc., Bethlehem, PA, USA) using E-Z anesthesia system
(Euthanex Corps, Palmer, PA, USA). Animals were mounted on stereotaxic surgical
device (Stoelting, Dale, IL, USA) which allows for injection of a substance into brain
regions with extreme precision, and monitored throughout the surgery in order to
maintain a sufficient level of anesthesia by a lack of response to a tail pinch. Following
anesthesia, animals were shaved to allow for access to the skin just above the skull and
wiped with hydrogen peroxide pads (Medline, Lo# QH17713L, Cat # MDS093917,
Mundelein, IL, USA). Following sterilization, an incision is made, approximately one
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inch, along the midline of the skull, and bregma is identified. Using the stereotaxic
device, and bregma as the reference point, the coordinates for the anterior/posterior (AP),
dorsal ventral (DV), and medial lateral (L) were calculated and the target sites were
marked. Using a Dremel tool, holes were drilled and an injection needle (Hamilton
Company, Reno, NV, USA) with the desired substance is inserted in to the BF (Young:
AP -.8 mm, L ±2.5 mm, and DV -8.0 mm; Aged: AP -1.1 mm, L ±2.8 mm, and DV -8.3
mm ) or LH (Young: AP -2.5 mm, L ±1.2 mm, and DV -9.0 mm; Aged: AP −2.9 mm, L
+1.6 mm, DV −9.4 mm relative). Coordinates for guide cannula implantation were
obtained from the Paxinos and Watson rat brain atlas (Paxinos & Watson, 1998). Lastly,
all animals were given a single dose of buprenorphine (0.01 mg/kg) to ease postoperative pain, given a triple antibiotic ointment (Acme United Corp., Fairfield, CT,
USA) and were monitored until complete recovery.
2.4 Stereotaxic Injections
Injections were implemented using a stereotaxic surgical device (Stoelting; Dale,
Illinois, USA). Each animal was injected individually and injections were performed in a
separate sterile environment.
2.4.1 Cholera Toxin B Subunit
To analyze basal forebrain afferent projections from the basal forebrain CtB was
injected in both aged (26-28 months) and young rats (2-3 months). Under isoflurane
anesthesia, 1ul of a retrograde neural tract tracer CtB (cholera toxin B subunit; Lot
#10331A1; stores at 2-8⁰ C; List Biological laboratories, Inc.) was injected unilaterally
into the basal forebrain (AP -.8 mm, L ±2.5 mm, and DV -8.0 mm; Aged: AP -1.1 mm, L
±2.8 mm, and DV -8.3 mm ) of animals (n=6-8/group). Animals were allowed one week
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(7 days) recovery. During this time handling, habituation to chambers, and food intake
was measured. Following immunohistochemistry, CtB infusion produced bilateral
expression within and around the substantia innominata. In some cases, mild expression
was seen in the ventral pallidum (VP) and medial septum (MS). CtB expression was
observed using Peroxidase (DAB) immunohistochemistry. Additionally, aged and young
rats showed similar spread of CtB expression following injections.
2.4.2 Lentiviral Injections
Lentiviral vectors are well recognized as good vehicles for gene delivery.
Lentiviral vectors are capable of efficiently transducing post-mitotic cells, and stably
integrating into the host genome allowing for long-term expression. A lentiviral vector
containing a DNA antisense strain, prepro-orexin, was injected into the LH to transduce
non-dividing cells long-term. This provides a unique ability to downregulate orexin
expression by gene mediated transfer. The transgene expression cassette SPWG-ORX
(Figure 2.1) was constructed at the University of South Carolina School of Medicine
Pharmacology, Physiology, and Neuroscience Virus Core Facility.
This lentivirus vector was produced by transfecting human embryonic kidney
(HEK) 293T cells with a transgene expression cassette, an envelope cassette, a packaging
cassette, and a vector cassette. The transgene expression cassette contains a prepro-orexin
DNA antisense, phosphoglyceatekinase-1 promoter for ubiquitous expression (PGK-1p),
an internal ribosome entry site (IRES), and enhanced green fluorescent protein (GFP)
expression marker, and a post-translational regulatory element, woodchuck hepatitis virus
post-transcriptional regulatory element (WPRE), which increases gene expression by
greater than fivefold. The envelope cassette encodes the vesicular stomatitis virus G
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glycoprotein gene which allows the vector to gain entry into the cells, and permits
transduction of several cell types, stabilizes the vector, and increases infection rate. The
packaging cassette, pCMVpR8.92, encodes lentiviral vector trans-regulatory elements
which encode for transcription factors necessary for effective transduction and replication
of the lentivirus. The vector cassette contains full-length vector RNA (HIV-1 Tatdependent vector) with cis-acting elements necessary for packaging, reverse
transcription, and stable expression by insertion into the host DNA (Cockrell & Kafri,
2007; Wong et al., 2006). Co-transfection produced virus stocks with 5x106 tu/µL.

Figure 2.1 SPWG-OX. Plasmid vector containing prepro-orexin
antisense gene construct.
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2.5 Entrainment
Prior to entrainment, all animals were handled daily for 7 days. The following
week, animals were handled and food intake was recorded for 7 days while animals were
habituated in microdialysis bowls (parabolic clear plastic bowls; Bioanalytical Systems,
Inc., West Lafayette, IN, USA; BAS). On the third week, the animals were food restricted
to 80% of their regular intake and underwent entrainment. During this time, animals were
monitored daily for food intake, water intake, and weight gain/loss. For the entrainment,
animals were either trained to associate a single palatable treat (bacon softie) with sudden
darkness or habituated in microdialysis bowls as controls. The food paired stimulus
(bacon/darkness) was chosen because this entrainment has been shown to increase in
prefrontal cortical acetylcholine release (J. Fadel, Sarter, & Bruno, 1999; Jim Fadel,
Moore, Sarter, & Bruno, 1996; D. Frederick-Duus et al., 2007; Inglis, Day, & Fibiger,
1994). This homeostatically relevant stimulus was given at the same time each day every
day at 10:00. The amount of time that lapsed prior to consuming the bacon softie was
recorded (latency to feed), and animals were taken back to their initial housing premises
30 minutes after consumption. Animals continued to be closely monitored for food
intake, water intake, and weight gain/loss. On the 7th day of training, the animals were
either given one last entrainment stimulus (E1) or not given the stimulus (C1) before
being sacrificed. Animals that were not trained at all (C2) were also sacrificed on this
day. Trunk blood was collected in BD vacutainers, centrifuged, and supernatant (plasma)
was stored at -20°C for ELISA.
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2.6 Trans-Cardial Perfusion and Tissue Collection
All experiments were completed with animals deeply anesthetized with isoflurane
and sacrificed. In the first two experiments (Chapter 3 and 4) all animals were
transcardial perfused using phosphate buffer saline (PBS) and 4% paraformaldehyde (4%
PFA). The pre-fixed brains were then removed from the skull placed in 4% PFA for an
additional 24-48 h. The following day the brains were blocked into 3 sections and sliced
using a vibratome (Electron Microscopy Sciences, OT-4000) into 50 micron thick slices.
The slices of brain tissue were collected and free floated in six wells of the 1X Trisbuffered saline (TBS; prepared with 0.08M Tris base (tris hydroxymethyl
aminomethane), 0.42M Tris Hydrochloride, 1.54M Sodium Chloride and diluted to 1%),
then transferred to 30% sucrose PBS, anti-freezing solution (500 ml 0.1 PB, 300 ml
ethylene glycol and 300 gm sucrose), for long term storage.
In experiments were animal brain homogenates were used for ELISA and
immunohistochemistry, brains were extracted and half the brain was placed directly on
dry ice and half post-fixed in a 4% paraformaldehyde solution. The flash frozen half of
the brain was then stored at -80ᵒ C to await further processing, and the post-fixed half of
the brain was blocked into 3 sections and sliced, similar to experiments 1 and 2, and
placed in antifreeze solution for long term storage.
2.7 Immunohistochemistry
The immunohistochemistry technique uses antibodies which are conjugated to
enzymes that catalyze reactions in order to form detectable compounds, either via
fluorescence or DAB, to visualize and localize specific antigens in a tissue samples in the
brain.
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2.7.1 Timeline
For immunohistochemistry studies, all animals maintained a strict timeline
(Figure2.2). Upon arrival, animals were habituated for 7 days. Animals were then
handled while food intake and body weight was measured daily for 7 days. Following
bowl habituation in microdialysis bowls in a separate room dedicated to animal testing,
animals were either given paired presentation of a sudden darkness in the testing room
with palatable food (E1; young n=8; aged n=8), no food paired stimulus training on the
last day (young C1 n =8; aged C2 n= 8) , or no food paired stimulus training on any day
(C2) while on an 80% diet restriction (80% of normal chow intake) (single bacon
flavored chow; a single paired presentation per day; always given at 11:00 h+/- 15min).
After seven consecutive days of training, the latency of the animals to consume the bacon
flavored chow (Bacon softies; Bioserve, Fleming, NJ) was generally less than 5 seconds
and rats were either presented the paired stimulus 1 h prior to perfusion with 4%
paraformaldehyde and .1M PBS (young E1 n=8; aged E1 n=8) or left in the parabolic
plastic bowls with no presentation of the food paired stimulus (young C1/C2 n=8; aged
n=8). The light were kept off 1 h post food presentation on each day (red light present for
trainee visualization). During the first two days animals which did not consume food
(bacon softie) after 5:00 minutes were left with food in chamber and time to latency was
considered 5:00 minutes. During this training no animals failed to exhibit latency
improvement during the 7 (E1) or 6 day trainings (C1). Animals categorized in group C2
were neither exposed to bacon treats nor darkness during training times (11:00).
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Figure 2.2 General Timeline of Immunohistochemistry experiment.

2.7.2 Injection Placement Verification
CtB staining using immunohistochemistry verified the CtB injection site
placement in each rat. The verification was conducted on 50 μm coronal sections of the
BF that were sectioned on the vibratome in 1x TBS and stored in anti-freezing solution
(500ml .1M PB, 300 ml ethylene glycol, 300 g sucrose). Free-floating sections were
placed in a petri dish and BF brain tissue sections were taken for staining. Sections were
washed thoroughly (5 rinses at 10 min each) in 1x TBS prior to immunohistochemistry of
αCtB (goat) (1:5000; Jackson ImmunoResearch Laboratories, West Grove, PA, USA cat#
705-005-003) overnight at room temperature followed by secondary antibody staining of
unlabeled donkey αgoat (1:200; Jackson ImmunoResearch Laboratories, West Grove,
PA, USA; Lot# 132096) at 2 h. Tissue was then washed and incubated in Goat Pap
(1:500; Jackson ImmunoResearch Laboratories, West Grove, PA, USA; Lot #11945) for
1.5 hs and washed again. Tissue sections were developed using DAB (Sigma-Aldrich co.,
St. Louis, MO, USA, Lot#MKCK2487) and 30% hydrogen peroxidase (VWR Life
Sciences, Solon, Ohio, USA, Lot # 18K1256212) to produce a brown staining of the CtB
injection site in the BF. Sections containing the CtB verification were mounted onto
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slides using 0.15% gelatin solution (.15g gelatin to 100 ml diH20). After drying
overnight, the tissue sections were further dehydrated via ascending ethanol
concentrations (50 – 100%) followed by Citrosol™ for 10 min in each. The slides were
cover slipped using DPX mounting medium (VWR International, West Chester, PA). CtB
injection site was verified (Figure 2.3) using a rat brain atlas (Paxinos & Watson
1998).Animals with inaccurate probe placement were excluded from further analysis of
any type.
2.7.3 Immunoperoxidase following CtB
For the immunoperoxidase staining the Fadel lab protocol, previously described
by Fadel and colleagues in 2002, was used (Fadel, Bubser et al. 2002). Perfused brains
stored in 4% paraformaldehyde were coronally sectioned (50 microns) using a vibratome.
All tissue for Immunohistochemical analysis was processed according to previously
described protocols with minor modifications (Frederick-Duus et al., 2007, Hagar, calva
Rat brains treated with CtB were double labeled for rabbit α-cFos (1:500;
Millipore Corp.,Temecula, CA ; Cat.# ABE457; Lot#3041795) and either goat αCTb(1:5000; List Biological laboratories Inc., Campbell, CA; Lot #7032A6), goat αChAT (1:3000; Millipore, Temecula, CA, USA;, Lot# 2762374, Cat#AB144), mouse αParvalbumin (PV; 1:3000; Sigma, Saint Louis, Missouri, USA; Cat#P3088, Batch#
016MA847V), vGluT (Millipore; Temecula, CA, USA; Cat#AB5905; Lot#2733748) , or
mouse α-Tyrosine Hydroxylase (TH; 1:3000; Immunostar, Hudson, WI; Lot# 907001;
Cat.#22941) to identify activated basal forebrain afferents, cholinergic neurons,
parvalbumin positive neurons, or dopaminergic neurons, respectively. Tissue was cleaned
in 1x TBS washes five times for 10 minutes, transferred into methanolic peroxide (90 ml

49

1x TBS, 10 ml, 100 % methanol and 2ml 30% hydrogen peroxide) for 15 minutes to
terminate any endogenous peroxidase activity, and to eliminate background staining, the
tissue was blocked with TBS+ (100 ml 10X TBS, 40ml normal horse serum, 2ml Triton
X-100, q.s. to 1L with pure diH20). Following blocking, sections were incubated in rabbit
α-cFos antibody for 48 h. Tissue was then incubated with biotinylated donkey anti-rabbit
secondary antibody (1:1000; Jackson ImmunoResearch Laboratories, West Grove, PA,
USA; Lot# 116529) for 1.5 h followed by horseradish peroxidase-conjugated streptavidin
(SHRP; 1:1,600; Jackson; cat# 016–030–084) for 1 h. cFos labeling was visualized by
adding 30% hydrogen peroxide (H202; 10 μl 30% H202 in 1ml TBS) to the tissue
sections in the presence of diaminobenzidine and nickel-cobalt solution (3.0 gm nickel
ammonium sulfate, 0.3 gm cobalt chloride q.s.100 ml with distill water) filtered through a
.2 µm syringe, generating a blue/black stain in cFos-immunoreactive areas . After an
appropriate development time, all sections were rinsed with 1X TBS (4 X 10 min).
For the second development, tissue was incubated in goat α-CTb antibody, αChAT, α-Parvalbumin, or α-TH for 48 h at room temperature on a nutator. Tissue was
washed (.1M PB 1x TBS) three times for 10 minutes and placed in unlabeled donkey
anti-goat antibody (1:200; Jackson ImmunoResearch Laboratories, West Grove, PA,
USA; Lot# 132096) or unlabeled donkey anti-mouse (1:200; Jackson ImmunoResearch
Laboratories, West Grove, PA, USA; Lot#87269) for 2 hr followed by followed by an
incubation in Goat PAP (1:500; Jackson ImmunoResearch Laboratories, West Grove,
PA, USA; Lot #11945) or Mouse PAP (1:500; Jackson ImmunoResearch Laboratories,
West Grove, PA, USA; Lot #131380). Tissue was developed using diaminobenzidine
(DAB) (Sigma-Aldrich co., St. Louis, MO, USA, Lot#MKCK2487), generating a brown
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immunoprecipitate to produce cFos nuclear labeling in either CTb, ChAT, PV, or THpositive fibers. Tissue was then mounted of microscope slides (VWR Life Sciences,
Radnor, PA, USA, and Cat # 16005-106) and dehydrated. After dehydration using
ethanol (50%-100%) and two 10 min soaks in Citrosol, the slides were cover slipped
using DPEX Mounting Medium (Electron Microscopy Sciences, Hatfield, PA, USA,
Cat# 13515) and microcover glass (VWR Life Sciences, Solon, Ohio, USA, Cat # 48393)
and left overnight to dry.
2.7.4 Immunoperoxidase following Lentiviral Injection
Post-fixed brains stored in 4% paraformaldehyde for 24 hr were coronally
sectioned (50 microns) using a vibratome. It should be noted that one hemisphere of the
rat brain was allocated for ELISA and one hemisphere was allocated to
immunohistochemistry. Rat brains injected with the lentivirus containing preproorexin
antisense (LV-PPOX) or lentivirus containing no antisense and only the GFP gene (LVGFP) were double labeled for rabbit αIb1A (1:5000; Wako Pure Chemical Industries;
Osaka, Japan; Cat# 019-19741; Lot# PTR2404), and either goat α-Orexin-A (OXA;
1:500; Santa Cruz Biotechnology Inc.; Dallas, TX, USA; Cat.# sc80263), goat α-ChAT
(1:3000; Millipore, Temecula, CA, USA;, Lot# 2762374, Cat#AB144), or mouse αParvalbumin (PV; 1:3000; Sigma, Saint Louis, Missouri, USA; Cat#P3088, Batch#
016MA847V) to identify microglia, and orexin neurons, cholinergic neurons, or
parvalbumin positive neurons, respectively. Tissue was cleaned in 1x TBS washes five
times for 10 minutes, transferred into methanolic peroxide (90 ml 1x TBS, 10 ml, 100 %
methanol and 2ml 30% hydrogen peroxide) for 15 minutes to terminate any endogenous
peroxidase activity, and to eliminate background staining, the tissue was blocked with
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TBS+ (100 ml 10X TBS, 40ml normal horse serum, 2ml Triton X-100, q.s. to 1L with
pure diH20). Following blocking, sections were incubated in rabbit α-Ib1A antibody for
48 h. Tissue was then incubated with biotinylated donkey anti-rabbit secondary antibody
(1:1000; Jackson ImmunoResearch Laboratories, West Grove, PA, USA; Lot# 116529)
for 1.5 h followed by horseradish peroxidase-conjugated streptavidin (SHRP; 1:1,600;
Jackson; cat# 016–030–084) for 1 h. cFos labeling was visualized by adding 30%
hydrogen peroxide (H202; 10 μl 30% H202 in 1ml TBS) to the tissue sections in the
presence of diaminobenzidine and nickel-cobalt solution (3.0 gm nickel ammonium
sulfate, 0.3 gm cobalt chloride q.s.100 ml with distill water) filtered through a .2 µm
syringe, generating a blue/black stain in cFos-immunoreactive areas . After an
appropriate development time, all sections were rinsed with 1X TBS (4 X 10 min).
For the second development, tissue was incubated in goat α-OXA antibody, goat
α-ChAT, or mouse α-Parvalbumin for 48 h. Tissue was washed (.1M PB 1x TBS) three
times for 10 minutes and placed in unlabeled donkey anti-goat antibody (1:200; Jackson
ImmunoResearch Laboratories, West Grove, PA, USA; Lot# 132096) or unlabeled
donkey anti-mouse (1:200; Jackson ImmunoResearch Laboratories, West Grove, PA,
USA; Lot#87269) for 2 h followed by followed by an incubation in Goat PAP (1:500;
Jackson ImmunoResearch Laboratories, West Grove, PA, USA; Lot #11945) or Mouse
PAP (1:500; Jackson ImmunoResearch Laboratories, West Grove, PA, USA; Lot
#131380). Tissue was developed using diaminobenzidine (Sigma-Aldrich co., St. Louis,
MO, USA, Lot#MKCK2487) to produce microglial labeling alongside either OXA,
ChAT, or PV neurons. After dehydration using ethanol (50%-100% 2 minutes each) and
Citrosol, the slides were cover slipped using DPEX Mounting Medium (Electron
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Microscopy Sciences, Hatfield, PA, USA, Cat# 13515) and micro-cover glass (VWR Life
Sciences, Solon, Ohio, USA, Cat # 48393) in a dark room. The slides were then dried for
48 hs prior to cleaning and imaging.
2.7.5 Immunofluorescence
CtB injected tissue was cut on the vibratome (50 microns) and stored in antifreeze
solution. For immunofluorescence, the tissue was washed (5 times for 10 minutes each),
placed in methanolic peroxide (90 ml 1x TBS, 10 ml, 100 % methanol and 2ml 30%
hydrogen peroxide) for 15 minutes, and blocked with TBS+ (100 ml 10X TBS, 40ml
normal horse serum, 2ml Triton X-100, q.s. to 1L with pure diH20) for 20 min. The
tissue was then triple labeled for rabbit α-cFos (1:500; Millipore Corp., Temecula, CA ;
Cat.# ABE457; Lot#3041795), goat α-CTb(1:5000; List Biological laboratories Inc.,
Campbell, CA; Lot #7032A6), goat α-ChAT (1:3000; Millipore, Temecula, CA, USA;,
Lot# 2762374, Cat#AB144), and mouse α-Tyrosine Hydroxylase (TH; 1:3000;
Immunostar, Hudson, WI; Lot# 907001; Cat.#22941) followed by incubation with
fluorescent secondary antibodies for rabbit (1:250), goat(1:100), and mouse (1:100) while
covered in the dark. Sections were then washed (5 rinses 10 minutes each), placed on
microscope slides using .15% gelatin solution, and covered in a box to dry overnight. The
slides were then dehydrated using ethanol (50% -100% 2 minutes each), cover slipped
using Permount mounting medium (Electron microscopy Sciences; Hatfield, PA, USA;
Cat #17986-05; Lot #162767) and sealed with fingernail polish (Sally Hansen). The
slides were then dried for 48 hs in a box to avoid light exposure prior to cleaning and
imaging.
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2.8 Microscopy
After dehydration and cover slipping, tissue sections were examined by light
microscopy (Nikon Eclipse E600). Two serial sections per animal at approximately 1.6
mm rostral to bregma were analyzed in a 400,000 mm2 area within each area. An average
was calculated for each animal based on those numbers.
2.8.1 Immunoperoxidase Photography
For all immunoperoxidase slides, images were visualized using the Nikon Eclipse
was fitted with CoolSNAP digital camera (Roper Scientific, Trenton, NJ, USA). In
partnership with the IP Labs Software (Scanalytics; Trenton, NJ, USA) and images were
imported to Adobe Photoshop 7.0 (Adobe Systems; San Jose, CA, USA) to adjust for
image size, contrast and brightness. Two images were taken of each animal and
peroxidase staining was quantified manually in each brain region (Figure 2.3). All images
were formatted into the same pixel size before quantification.

Figure 2.3 A representative pictograph of a brain tissue slice (Cl)
with cFos (black; white arrow), CtB (brown; blue arrow), and
cFos/CtB (astrick*) labeled neurons.
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2.8.2 Immunofluorescence Photography
Fluorescent images of brain tissue sections were acquired at 10x magnification
and identified based on corresponding rat atlas reference figures in the Rat Brain Atlas.
Fluorescence images were visualized using a Nikon E600 microscope or a Zeiss LSM700
(Zeiss; Oberkochen, Germany) equipped with a scan head with two photomultiplier tube
(PMT) detectors on an inverted Axio Observer Z1 stand. The Zeiss confocal microscope
contains four lasers which produce lines at 405nm, 635nm, 555nm and 488nm that allow
for visualization of triple labeled immunofluorescence.
2.9 Assays
To assess the cytokine activity, an ELISA was performed using both blood
plasma and brain homogenates from brain punches of the BF. Prior to analysis of brain
homogenates, protein levels were analyzed using a BCA protein Assay to
2.9.1 Timeline
For the microglia studies, animals were habituated for 7 days prior to stereotaxic
injections of the SPWG-OX virus (Figure 2.1). Following surgical injections, animals
were given food and water ad libitum for 3 weeks to allow the lentivirus to achieve
maximum efficacy while food intake and body weight measurements were taken daily.
The animals were then tested for cognitive/attentional deficits using food-paired stimulus
(bacon/darkness) and sacrificed with fresh brains removed and cut in half sagittaly. One
half of the brain was placed directly on dry ice in aluminum foil for preservation of fresh
tissue, and the other hemisphere was post-fixed in 4% paraformaldehyde in a glass 20ml
vial. The half of the brain designated to the ELISA study was processed for BF brain
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punches, and the post-fixed portion was sliced on the vibratome and tissues slices placed
in antifreeze solution in -20ᵒC freezer to await immunohistochemistry.
2.9.2 Plasmid Collection
To perform ELISA on blood plasma, blood was collected on ice in EDTA- treated
test tube (BD; Cat # 367835; Franklin Lakes, NJ, USA) prior to perfusion. All blood was
transferred on ice and then spun down for 15 minutes at 30,000 x g in a centrifuge
machine at 4ᵒC. The supernatant from the plasma was then transferred to an Eppendorf
tube and placed in a freezer at -80ᵒC.
2.9.3 Brain Homogenate Punches
For brain homogenates, punches were taken using a freezing microtome and the
rat brain atlas. Inactive lysis buffer cocktail was prep before taking brain punches (.8g
NaCl, 1ml 1% Tergitol, 10ml 10% glycerol, .315g Tris HCl; q.s. 100ml with HPLC grade
water). After taking brain punches, tissue was immediately weighed and placed in active
lysis buffer solution (100 µl phosphatase inhibitor cocktail, 100 µl protease inhibitor
cocktail, 10ml inactive lysis buffer) and lysis buffer was added at 1mg brain tissue: 5 µl
buffer solution in safe lock Eppendorf tubes (Eppendorf North America Inc., USA; Lot
J189122H; Cat #022363204) on ice. Before tissue is homogenized, 0.1g of .5mm
Zirconium Oxide beads (Next Advance; Troy, NY, USA; Cat# ZROB05) is added to
each safe-lock Eppendorf tube, and tubes are placed in a bullet blender (Next Advance;
Troy, NY, USA; Cat# G14G15) for 5 minutes at speed 10 in 4ᵒC. Tubes are aliquoted
into Eppendorf tubes (50ul each) and immediately placed in -80ᵒC freezer to await
ELISA or BCA Protein Assay.
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2.9.4 BCA Protein Assay
Brain Tissue homogenates are removed form -80ᵒC freezer and immediately
placed on ice. BCA working reagent is determined and working reagent is prepared (400
µl Reagent A, 20ml reagent B) and vortexed. Standards are prepared in accordance to the
BCA protein Assay Kit (Thermo Scientific; Rockford, IL, USA; Cat#23225) using
2mg/ml albumin standard ampules. Tissue samples are diluted at 1:12.5 in HPLC grade
water (4µl sample: 46 µl HPLC grade Water) in Eppendorf tubes. To a sample plate, 25
µl of tissue sample or standard is added to each well. To the same plate, 200 µl of
working reagent is added to each well using multichannel pipette. Plate is then placed in
oven at 37ᵒC for 30 minutes, and then cooled for 15 minutes outside the oven before
being read using a Biotek Synergy 2 Plate Reader (Biotek instruments Inc.; Winooski,
VT, USA; Cat #7131000).
2.9.5 ELISA
Blood plasma of ages and young animals were analyzed using a 12-Plex Th1/Th2
Bio-Plex kit (Bio-Rad Laboratories Inc.; Cat # 171K1002M; USA) immediately
following perfusion. To analyze cytokines, the Bio-Plex assay uses premixed coupled
magnetic beads and detection antibodies to detect a total of 12 different rat cytokines
including: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, GM-CSF, IFN-γ, and
TNF-α. Solutions for the assay were brought to room temperature for 45 minutes and
capture beads, lyophilized standards vial, secondary antibody, and tertiary antibody
(SAPE) were placed on ice. The dilution standards were prepared using the provided
diluent and reconstituted standard. Blood plasma or brain homogenates, previously stored
in Eppendorf tubes, were thawed and diluted to 1:4 (for plasma) or 1:3 (brain
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homogenates) with diluent. Tube of magnetic beads (575 µL) was then vortexed and
diluted into 15 ml conical tube ( Corning; Cat# 430790; Lot # 19418049; Mexico) with
assay buffer (5175 µL). Diluted beads were then added to be bottom of a 96-well plate,
followed by 50 μL of standards and samples using a P-1000 and P-200 multichannel
pipette. The assay plate was incubated on an orbital shaker plate for 1 h at room
temperature. After 3 washes with wash buffer using a wash station (MAGx2 protocol),
the detection antibody (300 µL) was added to each well along with the detection antibody
diluent (2700 µL), followed by a 30 minute incubation at room temperature on an shaker
plate. The plate was then run through the wash station (MAG 3x protocol) to remove left
over detection antibody. Finally the tertiary antibody, SAPE (60 µL) and assay buffer
(5940 µL), was added to each well using a multichannel pipette and the plate incubated
for ten minutes on a plate shaker. The plate was runt through a wash station (MAG3x)
and beads were resuspended in assay buffer (125 µL). The plate was read using a
Luminex Bio-Plex Multiplex plate reader that uses high photomultiplier voltage to detect
cytokines. Results were interpreted from a logarithmic standard curve.
2.10 Statistic analysis
Differences in latency to feed were tested by a one-way analysis of variance
(ANOVA) post hoc test with significance p < .05. Percent double labeled to either CtB,
ChAT, PV, or TH were tested by a two-way ANOVA. The between groups factors were
administration of food-paired stimulus (i.e. C1, C2, E1) and age (i.e. young and old),
where 2-3 months is considered young and 26-28 months is considered old. Young and
old groups were analyzed separately as determined as well. Sample size was determined
by power analysis for the food-paired stimulus study and suggested that 8 animals per
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group were sufficient to achieve statistical significance given an effect size of f = 0.6 and
α = 0.05. N-sizes for plasma measures were 8 per group. All values are expressed as
mean ± SEM. All statistical tests were done using GraphPad Prism version 5.02
(GraphPad Software Inc.; San Diego, CA). Immunohistochemical data were expressed as
percent of cFos/CTb, cFos/TH, cFos/ChAT, cFos/Parvalbumin relative to CTb, TH,
ChAT, or Parvalbumin labeled cells, respectively.
BCA protein assays were analyzed using Excel and protein contents (ug/ml) were
then interpolated in GraphPad Prism 9 using a standard curve. ELISA data (pg/ml) was
normalized to protein content (ug/ml) and graphed using an analysis of variance
(ANOVA) with significance set at p < 0.05. Cytokines were analyzed as one-way
ANOVA or paired/unpaired t-test.
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CHAPTER 3. AGE RELATED CHNAGES IN BF AFFERENT
ACTIVATION
Aim 1: To identify age-related changes in neuronal activation of basal forebrain
afferent population following a food-paired stimuli in aged and young rats.
3.1 Rationale
The ability to detect and interpret internal and external stimuli to make
appropriate decisions requires focusing on relevant stimuli. Many brain regions are
implicated in maintaining an adequate level of signal/noise ratio for stimulus
discrimination, and stimulus valence evaluation (Aitta-Aho et al., n.d.; Ronald P.A.
Gaykema et al., 1991; Morales & Margolis, 2017; Villano et al., 2017). Recent evidence
suggests that sensory and decision-making circuits must interact via a common neuronal
pathway designated to integrate signals in order to elicit an appropriate behavioral
response. The BF has been implicated in the integration of signals and plays a vital role
in top-down processes in which the BF moderates how attentional resources are allocated
(J. Fadel & Burk, 2010b; Viggiano et al., 2014). The heterogeneous afferent and efferent
neurons of the BF are capable of interpreting and communicating these diverse signals,
and it is important to note that the BF forms many bidirectional signaling pathways which
includes most of the cortical mantle and sensory processing circuits modulating different
aspects of the sensory decision-making process (I. Gritti et al., 2006; Hasselmo & Sarter,
2011; Laszlo Záborszky et al., 2018).
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The functional role of the BF efferents, particularly the BFCS, has been
extensively studied. Previous studies have established a role for cortically projecting
basal forebrain cholinergic neurons (BFCN) in the modulation of attention (Everitt &
Robbins, 1997; Lammers et al., 2018; McGaughy & Sarter, 1998). These anatomical
studies demonstrated that these cholinergic neurons are interspersed with GABAergic
projecting neurons and may form highly organized inputs onto specific cortical groups
which receive specific combinations of inputs to influence attention (Gielow &
Zaborszky, 2017; Ivana Gritti et al., 1993; Kondo & Zaborszky, 2016; Laszlo Zaborszky
et al., 2015). Hippocampal BF efferents have been shown to influence memory and
learning aspects of behavioral tasks. The control of these efferent signals is achieved
through a variety of inputs stimulating different cholinergic, and potentially GABAergic,
neurons. Several studies have defined BF afferent populations which contribute to this
input-output relationship. However, the role of these BF afferents during aging is yet to
be fully understood.
Evidence indicates that age-related cognitive deficits, particularly in memory,
learning, decision making and attention, are in part due to a dysregulation in the signaling
mechanisms of the BF; however, it is not yet known what particular afferent and local
neuronal pathways or populations may be implicated in this dysfunction. Behavioral
cognitive and attentional deficits have been demonstrated in both normal aging and
pathological age-related disorders have been associated with basal forebrain dysfunction
(Baxter & Chiba, 1999). Moreover, homeostatic dysfunction has been shown to disrupt
cognitive function in normal aged patients, and in rodent models suggesting a
relationship between aging and homeostatic dysfunction (J. R. Fadel et al., 2013; Herman
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et al., 2016; Teipel et al., 2018). Evidence suggests that the BFCS undergoes moderate
degenerative changes during aging which are related to mild attentional and cognitive
decline (Schliebs & Arendt, 2011). Thus, we aim to identify age-related changes in
specific BF afferent populations.
3.2 Hypothesis
Because there is growing evidence suggesting that BF neurons receive a specific
combination of inputs related to differing functions, first we predict that there are specific
BF afferent circuits involved in age-relate homeostatic dysfunction. I hypothesize that
age-related attentional deficits related to the attentional processing of homeostatically
relevant stimuli is associated with dysfunctional neuronal activation of specific BF
afferents. In my studies, I have reproduced a previously demonstrated age dependent
relationship between a dark/food-paired stimulus and age. Using this behavioral
technique in combination with neuronal tract tracing and histochemical analysis, I
examine the effects of aging on afferent input stimulation in the BF. I predict that
neuronal activation of specific BF afferents will be uncovered. This approach will reveal
several circuit motifs vulnerable to age-related dysfunction which will enable future
anatomical studies to define specific cell signaling mechanisms that are effected by aging
and age-related diseases.
3.3 Approach
All experiments were carried out in accordance with NIH Protocols and IACUC
approval. The methods described herein are an abbreviated version of those in Chapter 2:
General Methods. Experiments were carried out in six separate batches. All methods are
depicted in a timeline (Figure 3.1).
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Figure 3.1 Timeline of CtB Injection experiment on young (n=24) and age rats (n=24).
Rats were further divided into 3 subcategories based on food paired stimulus training (E1,
C1, and C2).
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All experiments were conducted using young (3-4 months) and aged (26-28
months) male Fisher 344/Brown Norway F1 hybrid rats (National Institute of Aging
Colony, Baltimore, Maryland, USA. Upon arrival, animals were randomly assigned to
receive C1 (no training), C2 (training on 6 of 7 days), or E1 (training all 7 days). All
animals received CtB Injections (Figure 3.2) following Habituation for 7 days.

Figure 3.2. A typical CTb deposit site.
(A) Diagram of SI region of the BF. (B) CTb deposit site (indicated by black
elongated arrow) following injection of CTb (brown) in the SI/VP region of a
young rat.

3.3.1

CTb Retrograde Tracer Injection
A retrograde neuronal tracer CTb (1ul) was injected unilaterally in the BF of aged

(26-28 months) (n=24) and young (2-3 months)(n=24) F344/Brown Norway F1 hybrid
rats (250-300g; National Institute of Aging Colony, Baltimore, MD, USA) following one
week of handling and habituation. Injections targeted the SI/NBM of the BF (Stereotaxic
Coordinates: AP -.8 mm, L ±2.5 mm, and DV -8.0 mm; Aged: AP -1.1 mm, L ±2.8 mm,
and DV -8.3 mm) Animals were allowed one week for recovery during which handling,
habituation to chambers, and food intake was measured. CtB infusion was used to
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produce bilateral expression. The injection site was later observed using
immunohistochemistry (Figure 3.2). Starting at Day 8 prior to CtB injection and daily
until day 28 when rats were perfused and brain tissue was processed for
immunohistochemistry, all animals were monitored daily for any changes in body weight
or food intake.
3.3.2 Food-paired training
During day 14-21 young or aged rats were categorized into 3 subcategories based
on food/darkness training assignments. Control groups (C1; aged n=8; young n=8) were
habituated in microdialysis bowls for 1 h until day 7 in which rats were perfused with 4%
paraformaldehyde 1 h after the completion of daily bowl habituation. Control groups
which received food/darkness training on day 1-6 (C2; aged n=8; young n=8) were only
habituated in microdialysis bowls on day 7 prior to perfusion. Experimental groups (E1;
aged n=8; young n=8) were given the food/darkness training daily for 7 days, and
animals were then perfused on day 7 1 h after being given the food/darkness stimulus.
The food/darkness training consisted of darkness (switching off the light) followed by the
presentation of a palatable treat (Bacon softie). During day 14-21 rats were given an 80%
diet restriction. Calculation for the daily amount each at would receive were taken from
food intake data taken one week prior.
3.3.3 Histology
Following perfusion with 4% paraformaldehyde, brains were removed and cut on
a vibratome in 1X TBS and placed in antifreeze solution for storage in -20ᵒC freezer.
Prior to staining, tissue was washed in 1x TBS, transferred into methanolic peroxide, and
blocked with TBS. Tissue sections were double labeled for rabbit α-cFos (1:500;
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Millipore Corp., Temecula, CA) and goat α-CTb (1:5000; List Biological laboratories
Inc.) to identify activated basal forebrain afferents. Following incubation in rabbit αcFos, sections were incubated biotinylated donkey anti-rabbit secondary antibody for 1.5
hs followed by horseradish peroxidase-conjugated streptavidin for 1 h. cFos labeling was
visualized by adding 30% hydrogen peroxide to the tissue sections in the presence of
diaminobenzidine and nickel-cobalt solution. After an appropriate development time, all
sections were rinsed with 1X TBS (4 X 10 min) and placed directly in goat α-CtB
primary antibody for 24 hs at room temperature. Tissue was then washed and placed in
unlabeled donkey α-goat secondary antibody for 2 hs at room temperature followed by
goat PAP for 1.5 h at room temperature. Tissue was then washed and visualized by
adding 30% hydrogen peroxide to the tissue sections in the presence of diaminobenzidine
to produce a brown staining (Figure 3.2).
For single-label immunohistochemistry to identify either CtB Density or cFos
density, free floating sections were incubated with a rabbit α cFos or goat αCtB antibody
for 48 hr at 4ºC followed by a biotinylated donkey α-rabbit or biotinylated donkey α-goat
secondary antibody for 1 ½ hs at room temperature, and horseradish peroxidase
conjugated streptavidin for 1 h at room temperature. Staining was developed using 0.3%
hydrogen peroxide and nickel-cobalt enhanced diaminobenzidine to yield blue-black
nuclei of activated neurons or CtB afferent fibers. All sections were mounted onto slides
with 0.15% gelatin, dried overnight, dehydrated (ethanol 50%-100%), delipidated
(Citrosol), and cover-slipped using DEPEX mounting medium.
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For immunofluorescence in the VTA, tissue was triple labeled for rabbit α-cFos
(1:500; Millipore Corp.), mouse α-TH (1:500; Immunostar) and goat α-CTb (1:5000; List
Biological laboratories Inc.) to confirm dopaminergic activation of BF afferents
n=4, young; n=4, aged). Perfusion and brain sectioning were similar to the methods
described in chapter 2. Tissue was then triple labeled for rabbit α-cFos, goat α-CTb, and
mouse α-Tyrosine followed by incubation with fluorescent secondary antibodies for
rabbit (1:250), goat (1:100), and mouse (1:100) while covered in the dark. Sections were
then washed and placed on microscope slides using .15% gelatin solution, and covered in
a box to dry overnight. Sections were mounted onto slides with 0.15% gelatin, dried
overnight in a dark box, dehydrated only and cover-slipped using Permount mounting
medium and finger nail polish.
3.3.4: Microscopy and Imaging
Histological experiments for single-labeled (cFos and CtB) neurons, and doublelabeled (cFos/CtB) neurons were visualized at 10x-20x magnification using a Nikon
E600 microscope fitted with a CoolSNAP digital camera. Immunoperoxidase photos
were captured using IP Lab Software. Fluorescence images were visualized at 10x-20x
magnification on a Zeiss LSM700 (Zeiss; Oberkochen, Germany) equipped with a scan
head with two photomultiplier tube (PMT) detectors on an inverted Axio Observer Z1
stand.
3.3.5 Data Analysis
For all immunohistochemistry experiments, single-labeled (cFos) and double
labeled (cFos/CtB) positive neurons were counted within the confines of a reticle fixed
into the eyepiece of the microscope. Counts for each brain region were determined
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by the total number of immunopositive nuclei/CtB labeled neurons and expressed as a
percentage of cFos labeled in CtB cells. Two representative images of each animal in
each region were averaged to obtain one data point. Single-label cFos and single-labeled
CtB was expressed as the density of immunopositive nuclei counted within the reticle
area (cFos or CtB nuclei/mm2) and qualitatively expressed in table format.
Statistical analyses of these data were analyzed by two-way ANOVA or unpaired
two-tailed t-test using GraphPad Prism 8 Software. To analyze the relationship between
age (young and old) and training effect (C1, C2, E1) a two-way ANOVA was performed.
Significant effects of CtB, cFos density, body weight, feeding latency, and food intake
between aged or young animals were tested using multiple unpaired t-tests or one-way
ANOVA (significant effects of treatment condition (i.e. E1, C1, C2) across age were
determined followed by Tukey’s multiple comparisons test). The significance level was
determined as p<0.05 for all analyses.
3.4 Results
3.4.1 Effects of Age on Latency to Feed
To confirm that aging can affect the cognitive ability to sense and attend to a
homeostatically relevant stimuli, food-paired (dark/bacon softie) stimulus training was
enacted (Figure 3.3). Latency to feed was used to test the ability to process the presentation
of a bacon softie following a quick shut off of the lights. A greater latency to feed was
expected for the aged E1; 26-28 months) group in comparison to their younger (E1; 2-3
months) counterparts over a 7 day period. Two trends are evident among the groups: both
groups show a general decrease in response latency over time and the age group had a
greater overall response latency than the young group. A two-way ANOVA indicated a
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significant difference between the age and young animal’s response latency (p<.0001; F
(1, 14) = 130.6; column factor). The ability for aged animals to respond and attend to the
conditioned stimulus was observably longer than young animals from day to day. A post
ho Turkeys Multiple Comparisons test was performed which revealed a significant
difference between Day 3-7 in aged and all days in young animals. Thus, the food-paired
stimulus (darkness bacon softie) was a successful indicator of the gap between aged vs.
young cognitive ability to attend to external homeostatically relevant stimuli. Previous
work showed food restricted aged rats have increased latency to food paired stimuli
compared to young control (D. Frederick-Duus et al., 2007; Danielle Frederick-Duus,
2008).

Figure 3.3 Food-Paired stimulus training over 7 days between aged and
young rats. Data reveals a significant increase in feeding latency of age
rats compared to younger counterparts (p<.0001; F (1, 14) = 130.6) and
between days (3-7) using Tukey’s post hoc analysis.
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3.4.2 Effects of Age on cFos Density
To confirm that aging can produce a significant decrease in activation,
immunohistochemistry was employed to measure the mean density of activation in several
brain regions including the PLC, ILC, IC, LH, CL, NAc, CEA, and VTA (Table 3.1). CFos
expression was measured (cFos nuclei per mm2) in C1, C2, and E1 groups of young and
aged animals. Density measurements for cFos were taken in a 0.49 mm x 0.49 mm area in
the center of the associated regions. For cFos counts within a region, total number was
represented as a cFos positive nuclei. A two-way ANOVA was used to indicate whether a
significant differences between E1, C1, C2 groups of young and aged animals in each
separate brain region. A post hoc Turkeys Multiple Comparisons test was performed to
reveal a significant difference between groups of young and aged animals.
There was a significant increase in cFos density of young E1 animals vs. aged E1
groups in the PLC (P=.0437; F (1, 6) = 28.2), NAc (p=.0344; F (1, 6) =17.4), LH (p=.0356;
F (1,6)= 39.2) and VTA (p=0.013; F (1, 6) = 26.78). A trend in the ILC (p=.059; F (1, 6) =
28.9) reveals a decrease in young cFos activation compared to aged groups. Following
comparisons of age groups, a quantification of the cFos density in each group (C1, C2, E1)
for both young and aged rats using a post hoc analysis, Tukeys Multiple Comparisons test,
was performed which revealed a significant decrease in age E1 groups vs young E1 groups
in the PLC (p=.0319), NAc (p=.0147), and VTA (p=.0011). A significant increase in aged
E1 compared to young E1 groups in the ILC (p=.0411) was also revealed which indicated
that the ILC and PLC have opposing cFos activation in response to a food paired stimulus.
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Table 3.1 Density of cFos indicated via cFos labeled nuclei (per mm2). Table illustrates cFos density of labeled nuclei in PLC, ILC,
IC, LH, Cl, NAcc, CeA, and VTA following food paired stimulus (C1, C2, E1). There is a significant increase between young E1
compared to old E1 groups (with *=P<.05) of PLC, NAcc, and VTA. The ILC demonstrates an opposing trend with aged showing
cFos Density (cFos nuclei per mm2)
Young
Area

Old
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C1

C2

E1

C1

C2

E1

PLC
ILC
IC
LH
Cl
NAc

21.94
22.53
14.80
16.42
18.28
33.16

22.86
22.04
13.88
14.92
17.89
30.20

34.69*
17.69
15.95
18.31*
16.93
44.30*

22.45
20.41
12.93
15.21
17.74
27.40

23.45
22.45
11.56
16.32
17.85
34.69

22.96
15.82
16.33
14.21
15.31
37.31

CeA

26.02

20.41

19.73

20.41

18.37

19.23

VTA
20.41
17.96
29.25*
13.61
12.93
15.31
higher levels of cFos density compared to young. This suggests a potentially significant role in the processing of homeostatically
relevant stimuli which is lost during aging.

Effects of Age on CtB density
Using immunohistochemistry, CtB fibers where quantified for several BF afferent
regions including the PLC, ILC, IC, LH, CL, NAc, CeA. There was no significant
difference in CtB fiber density between young and age animals. This was confirmed
using a t-test between young and aged groups in each individual BF afferent regions.
However, CtB density was observably uniform across age (young, aged) and group (E1,
C1, C2). Density of fiber was determined using a 0.49 mm x 0.49 mm area in the center
of the associated regions and were quantified using Excel.

Figure 3.4 CtB density of several BF afferents including PLC, ILC, IC,
LH, NAc, CeA, and VTA showed no significant changes indicating no BF
Afferent loss between young and aged animals.
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3.4.3

Effects of Age and Food-paired Stimulus in Cortical Regions
To determine the effects of aging on BF afferent activation, immunohistochemistry

was employed to measure the number of cFos/CtB neurons over CtB+ neurons in the
several brain regions including the PLC, ILC, and IC (Figure 3.5). Analysis using light
microscopy and diaminobenzidine (DAB) reveal cFos labeled nuclei (black) and CTb
labeled soma (Brown). Double labeling of CTb-cFos positive cells are expressed as a
percentage of the total CTb labeling for PLC, ILC, and IC in young and aged rats. A twoway ANOVA revealed a significant variation between stimuli (C1, C2, E1; p=0.003; F
(2,33)=10.6). Following a two-way ANOVA paired with a Tukey’s Multiple Comparison
test, the PLC shows a significant increase in the percentage of double labeled neurons when
exposed to dark-food paired stimulus 1 h prior to perfusion (young E1 vs age E1; p=0.0397)
and between young rats which received food-paired stimulus training (E1) and controls
(C1 vs E1; p=0.0131) (C2 vs E1; p=0.001). In the ILC, a two-way ANOVA reveals a
stimulus effect (Column factor; E1, C1, C2; p<0.0001). However, no changes in amount
of basal forebrain afferent activation of younger rats (E1) compared to age counterparts
(E1). Interestingly, the ILC shows an opposing effect between column factor (stimuli;
p=0.04111; F (2,33)=12.1) which is exemplified in Tukey’s Multiple Comparison test
between the young E1 groups which have a significantly lower activation of basal
forebrain afferents compared to controls (E1 vs. C1; p=0.001)(E2 Vs. C2; p=0.0013), and
opposing effects in aged E1 and control groups (E1 vs. C1; p=0.0158)(E2 Vs. C2;
p=0.0003). The IC has no significant age-related change in the basal forebrain afferent
activation following a food paired stimulus (E1) in young rats compared to aged rats using
a two-way ANOVA.
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Figure 3.5 Double labeled immunohistochemistry of cortical regions. (A) A significant
change between young and aged rats both between age groups and following food paired
stimulus (E1) and controls (young C1 vs C2) in cFos labeled CTb neurons in the PLC.
(B)(E)(H) Representative image (10X) of cFos/CTb+ double labeling (black arrow) in the
PLC, ILC, and IC in young rat after the food paired stimulus (E1), respectively. (C)(F)(I)
Representative image (10X) of an old rat after the food paired stimulus (E1) in the PLC, ILC,
and IC, respectively. (D) Double labeled cFos/CTb in the ILC following food paired stimulus.
No significant changes in double labeling between age groups. However stimulus groups
(young C1 vs E1 and C2 vs E1) show changes in ILC in cFos/CTb labeled neurons. (G) No
significant changes between age group or stimuli group double labeling (cFos/CTb).
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3.4.5 Effects of Age and Food-paired Stimulus in Medial Regions
To investigate the effects of aging on BF afferent activation in medial brain regions,
immunohistochemistry was used to measure the number of cFos/CtB neurons over CtB+
neurons in the medial brain regions including the NAc and Cl (Figure 3.6). The two-way
ANOVA was used on data which was obtained using light microscopy and DAB reveal
cFos labeled nuclei (black) and CTb labeled soma (Brown). Black arrows indicated
cFos/CtB+ neurons in each brain region. Double labeling of CTb-cFos positive cells is
expressed as a percentage of the total CTb labeling for young and aged rats. In the NAc, a
two-way ANOVA revealed a significant variation between stimuli (C1, C2, E1; p=0.0004;
F (2, 33) =10.16). Following a two-way ANOVA paired with a Tukey’s Multiple
Comparison test, the PLC shows a significant increase in the percentage of double labeled
neurons when exposed to dark-food paired stimulus 1 h prior to perfusion (young E1 vs
age E1; p=0.0086). Tukey’s Multiple Comparison test also revealed a significant difference
between young rats which received food-paired stimulus training (E1) and controls (C1 vs
E1; p=0.0229) (C2 vs E1; p=0.0092), and between aged E1 and C1 control groups
(p=0.0422). In the Cl, following a two-way ANOVA, there was no significant age-related
change (row factor) in BF afferent activation following a food paired stimulus) in young
rats compared to aged rats. Additionally, Tukey’s Multiple Comparison test did not
determine any between group and age effects in the Cl.
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Figure 3.6 Double labeled immunohistochemistry of medial regions. (A) Double labeled
cFos/CTb in the NAcc following food paired stimulus. A significant change in double
labeling between age groups (young E1 vs Old E1) and between stimuli groups (young
C1 vs E1 and C2 vs E1)(old C1 vs E1. (B)(E) Representative image (10X) of cFos/CTb
double labeling(black arrow) in the Cl and Nac in young rat after the food paired stimulus
(E1), respectively. (C)(F) Representative image (10X) of an old rat after the food paired
stimulus (E1) in the Cl and Nac, respectively. (D) No significant change between young
and old rats both between age groups and between stimuli groups (C1, C2, E1) in cFos
labeled CTb neurons in the Cl.
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3.4.6

Effects of Age and Food-paired Stimulus in Caudal Regions
To test the hypothesis that aging causes dysregulation of BF afferent activation,

using immunohistochemistry, I measured the number of cFos/CtB neurons over CtB+
neurons in the caudal brain regions including the LH, CeA, and VTA following a foodpaired stimulus (Figure 3.7). In the LH, a two-way ANOVA resulted in a no significant
age or stimuli factor changes in basal forebrain afferent activation following a food paired
stimulus. (E1) Tukey’s Multiple Comparison test did not determine any across groups or
age effects. The C2 and E1 young groups showed a slight trend (p=.1768). However, a
greater trend between young E1 and aged E1 groups is present (p=0.0565).
Curiously, analysis of the CeA reveals a significant decrease in the food
conditioned young rats who did not receive the bacon treat stimulus on the 7th day (C2)
compared to habituated controls (C1) following a two-way ANOVA (column factor;
stimuli; p=0.0473; F(2,33) = 18.683) paired with a Tukey’s Multiple Comparison test
(Young C1 vs. C2; p = .0485). Additionally a slight trend between young trained rats (E1)
and aged trained rats (E1) is present (p=0.0657).
The VTA, following a two-way ANOVA, confirms a significant change in row
factor (age; p<0.0001; F (1, 33) = 25.77) and column factor (stimuli; p=0.0011; F (2, 33)
= 8.487). Moreover, there is a significant difference between young E1 and control groups
(E1 vs C1; p<0.001) (E1 vs C2; p<0.0001). There is also a significant different between
young and aged E1 groups (p=0.001). No other significant changes are present.
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Figure 3.7 Double labeled immunohistochemistry of caudal regions. (A) No significant
change between young and old rats both between age groups and stimuli groups (C1, C2,
E1 in cFos labeled CTb neurons in the LH. (B)(E)(H) Representative image (10X) of
cFos/CTb double labeling (black arrow) in the LH, CeA, and VTA in young rat after the
food paired stimulus (E1), respectively. (C)(F)(I) Representative image (10X) of an old
rat after the food paired stimulus (E1) in the LH, CeA, and VTA, respectively. (D)
Double labeled cFos/CTb in the CeA following food paired stimulus. No significant
changes in double labeling between age groups. However stimulus groups (young C1 vs
C2 show no changes in cFos/CTb labeled neurons. (G) A significant change between age
groups (young vs old E1) and stimuli groups (young C1 vs E1 and C2 vs E1) in double
labeling (cFos/CTb).
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3.4.7 Dopaminergic neurons of the VTA
To analyze activational changes in the dopaminergic population of neurons in the
VTA, BF afferent activation of dopaminergic neurons was performed using double
immunofluorescence (Figure 3.8). Pictographs of double labeled and triple labeled
neurons were analyzed (Figure 3.9) and doubled labeled neurons in the VTA from each
group were counted manually and a two-way ANOVA revealed no significant change in
cFos/TH labeled neurons between groups. Triple labeled immunofluorescence revealed
that the BF inputs (green; CtB) originating in the VTA were immunopositive for cFos
and TH.

Figure 3.8. Double Labeled Immunohistochemistry. No significant
difference between young and aged dopaminergic activation following
food-paired stimulus.
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A

B

50µm

C

D

Figure 3.9. Immunohistochemistry and Immunofluorescence. (A)(B)
Representative pictures of the VTA of young (left) & aged (right) showing cFos
(black) and TH (brown) labeled neurons after DAB immunohistochemistry.
(C)(D) Representative images of immunofluorescence using TH (Red), cFos
(blue) and CtB (green) in the VTA.
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3.5 Discussion
These data suggest that there are age-related changes in behavioral and neuronal
activation associated with the BF in response to a food-paired stimulus. Interestingly, an
age-related loss in neuronal activation, but not in BF input can be seen following the
presentation of a food-paired stimulus. Moreover, age-related attentional deficits related
to the attentional processing of homeostatically relevant stimuli are associated with agerelated dysfunctional neuronal activation of specific BF afferents including the PLC, LH,
NAc, and VTA.
3.5.1 Latency to Feed
The latency to feed behavioral paradigm demonstrates the animals’ ability to
recognize hunger and divert attentional resources to fulfilling that hunger. When rats are
placed on an 80% food restricted diet and presented with a conditioned food-paired
stimulus (darkness/bacon softie), the aged animals showed a greater latency to feed over
the 7 day period than the young animals. This demonstrated an attententional imbalance
to homeostatically relevant cues in aged animals. The significantly different behavioral
response between age and young rats leads to the conclusion that aged rats have a
cognitive impairment related to processing attentional stimuli associated with food
intake. Interestingly, this phenomenon is seen in aged humans (J. E. Morley, 2001; John
E. Morley & Thomas, 1999) which indicates a conserved behavioral deficit. Moreover,
the feeding latency mirror the BF afferent neuronal dysfunction seen between full trained
(E1) aged and young rats in the PLC, LH, NAc, and VTA which suggests that this
behavioral deficit is associated with specific BF inputs.
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Previously, studies in our lab have shown that feeding latency is mediated in part
by orexin and attributed to a loss in BF cholinergic innervation of the PLC (Jim Fadel &
Frederick-Duus, 2008; Kessler et al., 2011). Studies have also demonstrates a bilateral
innervation between the PLC and BF which may be involved in recruitment of cognitive
resources in order to respond to homeostatically relevant external cues (TashakoriSabzevar & Ward, 2018). Together these data suggest that age-related homeostatic
attentional deficit, observed in rats and humans, and may be due to a cognitive
impairment.
3.5.2 cFos and CtB Density
cFos is a proto-oncogene that is expressed in neurons following depolarization.
Using immunohistochemistry, the protein product, cFos protein, can be used as a marker
for neuronal activity. In this study, I characterized brain regions showing cFos activation
in rats following entrainment using a food-paired stimulus for 7 days (E1), and compared
these to levels of activation in untrained (C1) or 6 day trained (C2) control groups of both
young and aged rats. Our results show that there is a significant decrease in neuronal
activation of aged rats in the PLC, NAc, LH, and VTA which indicated overall neuronal
dysfunction in aged rats in these brain region.
To test the hypothesis that the neuronal dysfunction occurring between aged and
young groups is not due to a loss in BF afferent neurons, CtB density was measured using
immunohistochemistry for the CtB retrograde tracer previously injected in the BF of
young and aged animals. T-test reveal no significant difference between aged and young
rats in any brain areas of interest including the PLC, ILC, IC, LH, NAc, CeA and VTA.
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Thus, we concluded that the neuronal dysfunction is not due to BF afferent loss but
perhaps the dysfunctional regulation of BF afferent regions.
3.5.3 Age-related effects of food paired stimulus
Previous studies have suggested that age induced homeostatic disturbances
leading to a decrease in food intake and weight loss precede cognitive decline and MCI
(Cova et al., 2016; Danielle Frederick-Duus, 2008; Johnson et al., 2006). To test the
hypothesis that specific BF afferents are associated with this age-related dysfunction, I
administered a homeostatically relevant stimulus, previously shown to be effected by the
aged condition. Aged rats showed a significant decrease in afferent activation following
entrainment in several brain regions suggesting a role in age-related input alterations that
may correlate with homeostatic dysfunction in the BF. The BF plays an important role in
the information processing and integrating several and receives several inputs from
various brain regions. The dysfunctional signaling of inputs to the BF neurons may
contribute in some way to neuronal dysregulation seen during aging. Thus, the BF
afferents experiencing neuronal dysregulation are considered vulnerable to age related
changes, and identifying these vulnerable populations may contribute to our
understanding of aging, and age-related diseases.
The PFC and IC send highly organized bilateral projections between cortices and
the BFCS (Chaves-Coira, Rodrigo-Angulo, et al., 2018; Ronald P.A. Gaykema et al.,
1991). Following entrainment, neuronal activation following a food-paired stimulus
revealed an age-related decrease in neuronal activation of aged rats compared to young
rats in the PLC but an opposite effect was seen in the ILC. Moreover, the IC did not show
significant age-related effects. The ILC and PLC have both been shown to send major
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connections to the BF (Vertes, 2003; L. Zaborszky et al., 1997; Laszlo Zaborszky et al.,
2015).. The opposing effects seen in the PLC and ILC may be due to their differing roles
in mediating both fear/extinction and reward memories. The PLC is thought to exert topdown control over subcortical structures, including the BF, to regulate appropriate
behavioral responses. Importantly, the PLC and ILC regulate the expression and
suppression of fear and learning in rodents, respectively. Thus, one may conclude that the
opposing effects of the BF afferents, PLC and IL, are due to their role in mediating such
effects, and that these circuits are highly effected by age-related cognitive neuronal
dysfunction. The IC, however, has been shown to activate in response to one’s current
interoceptive state which has been shown to have age-related dysregulation associated
with the age-related loss of orexin (Hagar et al., 2017). Interestingly, the brain region
responsible for the production of orexin, LH, had a trend which revealed an age-related
loss in neuronal activation of BF intended circuits. Thus, orexinergic innervation of the
BF and IC may contribute to the slight trends of neuronal dysfunction seen in aged
animals.
Appetitive food stimuli have been shown to stimulated dopamine transmission in
the core of the NAc (Bassareo & Di Chiara, 1999) and is a significant player in
controlling the biological drives necessary for survival including feeding, reproduction,
and reward/motivation (Boswell & Kober, 2016; Pratt et al., n.d.; Rebec et al., 1996). A
significant increase in neuronal activation of BF afferents between E1 and control groups
(C1,C2) of young animals located in the NAc was observed following a food-paired
stimulus. Interestingly, the LH, IC, and PFC have been shown to innervate the NAc
which are involved in cognitive processing of functions related to reward/reinforcement
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(Brog et al., 1993). Furthermore, the NAc and VTA share an intimate pathway which is
highly involved in motivational recruitment of attention by homeostasis-associated cues
(Tashakori-Sabzevar & Ward, 2018). Thus, it was not surprising to see that the VTA also
showed an increase in E1 neuronal activation in young animals compared to controls. The
VTA and NAc also showed an age-dependent effect on entrained (E1) animals where
aged rats showed a significant decrease in neuronal activation of BF afferent compared to
young which suggests that this effect is blunted during aging. However, the exact cause
for this neuronal dysfunction is unknown.
Like the BF, the VTA hosts a heterogeneous neuronal population. Previous,
reports reveal a robust dopaminergic inputs in the basal forebrain from the ventral
tegmental area (Zahm & Trimble, 2008). This data suggests that dopaminergic neurons
from the ventral tegmental area may play a role in the processing of homeostatically
relevant conditioned stimuli. However, there may be other subpopulations from the VTA
that send projections in response to such a stimulus that the BF is mediating (Ronald P.A.
Gaykema & Zaborszky, 1997; Hur & Zaborszky, 2005). Moreover, it has been suggested
that PFC projecting cholinergic neurons in the BF receive input from the VTA (Gielow &
Zaborszky, 2017). This may indicate that a circuit motif between the VTA>BF>PFC
plays a role in mediating the attentional and cognitive decision making processes of
homeostatically relevant cues, and that this circuit is greatly hampered during aging. This
may indicate a circuit motif which is vulnerable to aging and age-related changes.
Together, this approach has revealed several BF afferents areas that are
potentially vulnerable to age-related dysfunction, which will enable future anatomical
studies to define specific cell signaling mechanisms that are effected by aging and age85

related diseases. Additionally, a circuit motif is revealed which is blunted during aging.
Thus, these studies indicate a potential age-related mechanism which may precede and
predict cognitive decline.
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CHAPTER 4. AGE-RELATED CHANGES IN BF NEURONAL
ACTIVATION
Aim 2: Identify age-related changes in neuronal activation of cell populations in
the basal forebrain.
4.1 Rationale
Alzheimer’s disease is associated with BFCS cell loss and degeneration,
specifically in the SI (Wolf et al., 2014). Similarly, moderate degenerative and cognitive
changes have been described in normal aging (M. J. Grothe et al., 2016; Wolf et al.,
2014). Extensive evidence involving the manipulation of the BFCS has shown that
lesions to the BFCS produce similar cognitive and attentional changes seen in normal
aged and AD patients (J. R. Fadel et al., 2013; McGaughy, Kaiser, & Sarter, 1996).
However, the role of GABAergic and glutamatergic neurons in the BF has not been as
extensively studied.
Some evidence has shown that excitation of the glutamate receptors in the BF can
excite cholinergic neurons to release ACh in the PFC. This paired with research stating a
role for GABAergic neurons, through the use of GABAergic agonist (chlordiazepine), in
decreasing BF cholinergic efflux of ACh suggests that GABAergic and glutamatergic
neurons play an important role in mediating BF cholinergic transmission (Jim Fadel et
al., 1996; Holly Moore et al., 1992; M. F. Sarter & Bruno, 1994).
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In immunohistochemistry studies comparing calcium binding protein
Parvalbumin (PV) and choline acetyl transferase (ChAT), a cholinergic marker,
GABAergic neurons tend to outnumber cholinergic neurons 2:1 (M. Sarter & Bruno,
2002). Thus, it is widely accepted that, compared with the number of cholinergic
neurons, an equal number of GABAergic neurons project to the cortex in congruence
with the BFCS (Ivana Gritti, Mainville, Mancia, & Jones, 1997b; Laszlo Zaborszky et al.,
1999). It is also believed that glutamatergic axons from the Prefrontal Cortex (PFC)
terminate exclusively on the noncholinergic neurons on the BF and that glutamatergic
containing neurons project to the PFC (Laszlo Zaborszky et al., 1999). This suggests a
bidirectional relationship between the PFC and, several populations of neurons in the BF
including GABAergic, glutamatergic, and cholinergic neurons. However, little is
understood about the behavioral effects on GABAergic and glutamatergic neurons in the
BF, it can reasonably hypothesized that GABAergic and glutamatergic neurons in the SI
may play a role in mediating cognitive and attentional processes and that these processes
may undergo age-dependent alterations similar to what is seen in cholinergic neurons of
the BF .
4.2 Hypothesis
Because there is growing evidence suggesting that the heterogeneous population
of neurons in the BF may be intimately involved in mediating the BFCS, I predict that
there are specific BF neuronal cell populations that are involved in age-relate homeostatic
dysfunction. I aim to identify a change in activation of GABAergic and glutamatergic
neurons, following a homeostatically relevant stimulus previously described, between
young and aged rats. Furthermore, I hypothesize that age-related attentional deficits
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related to the attentional processing of homeostatically relevant stimuli is associated with
dysfunctional neuronal activation of specific BF populations. In my studies, I have
reproduced a previously demonstrated age dependent relationship between a dark/foodpaired stimulus and age. Using this behavioral technique in combination with neuronal
histochemical analysis, I examine the effects of aging on local BF stimulation in the SI.
This approach will enable future anatomical studies to define specific cell signaling
circuits between BF afferents and local BF neurons to reveal the mechanisms that are
effected by aging and age-related diseases.
4.3 Approach
All experiments were carried out in accordance with NIH Protocols and IACUC
approval. The methods described herein are an abbreviated version of those in Chapter 2:
General Methods. Experiments were carried out in six separate batches. All methods are
depicted in a timeline (Figure 3.1). All experiments were conducted using young (3-4
months, 250-300g) and aged (26-28 months, 450-550g) male Fisher 344/Brown Norway
F1 hybrid rats (National Institutes of Aging Colony, Baltimore, Maryland, USA).
Animals were ordered in four separate batches. Upon arrival, animals were randomly
assigned to receive C1 (no training), C2 (training on 6 of 7 days), or E1 (training all 7
days). All Animals received CtB Injections following Habituation for 7 days and were
restricted to an 80% diet of normal ad libitum food weights.
4.3.1 Food-paired training
During day 14-21 young or aged rats were categorized into 3 subcategories based
on food/darkness training assignments. Control groups (C1; aged n=8; young n=8) were
habituated in microdialysis bowls for 1 h until day 7 in which rats were perfused with 4%
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paraformaldehyde 1 h after the completion of daily bowl habituation. Control groups
which received food/darkness training on day 1-6 (C2; aged n=8; young n=8) were only
habituated in microdialysis bowls on day 7 prior to perfusion. Experimental groups (E1;
aged n=8; young n=8) were given the food/darkness training daily for 7 days, and
animals were then perfused on day 7 1 h after being given the food/darkness stimulus.
The food/darkness training consisted of darkness (switching off the light) followed by the
presentation of a palatable treat (Bacon softie). During day 14-21 rats were given an 80%
diet restriction. Calculation for the daily amount each at would receive were taken from
food intake data taken one week prior.
4.3.2 Histology
Following perfusion with 4% paraformaldehyde, brains were removed and cut on
a vibratome in 1X TBS and placed in antifreeze solution for storage in -20ᵒC freezer.
Prior to staining, tissue was washed in 1x TBS, transferred into methanolic peroxide, and
blocked with TBS. Tissue sections were double labeled for rabbit α-cFos (1:500;
Millipore Corp., Temecula, CA ; Cat.# ABE457; Lot#3041795). Tissue was then
incubated with biotinylated donkey anti-rabbit secondary antibody for 1.5 hs followed by
horseradish peroxidase-conjugated streptavidin (SHRP; 1:1,600; Jackson; cat# 016–030–
084) for 1 h. cFos labeling was visualized by adding 30% hydrogen peroxide (H202; 10
μl 30% H202 in 1ml TBS) to the tissue sections in the presence of diaminobenzidine and
nickel-cobalt solution (3.0 gm nickel ammonium sulfate, 0.3 gm cobalt chloride q.s.100
ml with distill water) filtered through a .2 µm syringe, generating a blue/black stain in
cFos-immunoreactive areas. After an appropriate development time, all sections were
rinsed with 1X TBS (4 X 10 min).
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For the second development, tissue was incubated in and either goat α-ChAT
(1:3000; Millipore, Temecula, CA, USA;, Lot# 2762374, Cat#AB144), mouse αParvalbumin (PV; 1:3000; Sigma, Saint Louis, Missouri, USA; Cat#P3088, Batch#
016MA847V), or vGluT (Millipore; Temecula, CA, USA; Cat#AB5905; Lot#2733748)
to identify activated BF cholinergic neurons, GABAergic, or glutamatergic neurons,
respectively. After 48 h at room temperature on a nutator, tissue was washed (.1M PB 1x
TBS) 3 times for 10 minutes and placed in unlabeled donkey anti-goat antibody (1:200;
Jackson ImmunoResearch Laboratories, West Grove, PA, USA; Lot# 132096) or
unlabeled donkey anti-mouse (1:200; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA; Lot#87269) for 2 h followed by followed by an incubation in Goat
PAP (1:500; Jackson ImmunoResearch Laboratories, West Grove, PA, USA; Lot
#11945) or Mouse PAP (1:500; Jackson ImmunoResearch Laboratories, West Grove,
PA, USA; Lot #131380). Tissue was developed using diaminobenzidine (DAB),
generating a brown immunoprecipitate to produce cFos nuclear labeling in either CTb,
ChAT, PV, or TH-positive fibers. Tissue was then mounted of microscope slides (VWR
Life Sciences, Radnor, PA, USA, Cat # 16005-106) and dehydrated. After dehydration
using ethanol (50%-100%) and two 10 min soaks in Citrosol, the slides were cover
slipped using DPEX Mounting and microcover glass and left overnight to dry before
being cleaned for imaging.
4.3.3: Microscopy and Imaging
Histological experiments for double-labeled (cFos and PV/ChAT/vGluT) neurons,
were visualized at 10x-20x magnification using a Nikon E600 microscope fitted with a
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CoolSNAP digital camera. Immunoperoxidase photos were captured using IP Lab
Software.
4.3.4 Data Analysis
For all immunohistochemistry experiments, neurons were counted within the
confines of a reticle fixed into the eyepiece of the microscope. Counts for each brain
region were determined by the total number of immunopositive cFos and
ChAT/PV/vGluT labeled neurons and expressed as a percentage of cFos labeled in each
respective neuronal cell. Two representative images of each animal in each region were
averaged to obtain one data point.
Statistical analyses of these data were analyzed by two-way ANOVA or unpaired
two-tailed t-test using Graphpad Prism 8 Software. To analyze the relationship between
age (young and old) and training effect (C1, C2, E1) a two-way ANOVA was performed.
Significant effects of CtB, cFos density, body weight, feeding latency, and food intake
between aged or young animals were tested using multiple unpaired t-tests or one-way
ANOVA (significant effects of treatment condition (i.e. E1, C1, C2) across age were
determined followed by Tukey’s multiple comparisons test). The significance level was
determined as p<0.05 for all analyses.
4.4 Results
The basal forebrain contains several nuclei and neuronal populations including
cholinergic, glutamatergic and GABAergic neurons. To test the hypothesis that changes in
neuronal activation during aging may be neuronal subtype specific, double label
histochemistry using α-CFos and either α-ChAT or α-Parvalbumin or α-vGluT was
performed. A two-way ANOVA followed by a Tukey’s Multiple Comparison test
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demonstrated a significant changes between column factors (stimuli) and a slight trend
between row factor (age)(p=.09211; F (3,30)=2.8.11) in activated PV cells. A significant
change in PV neuronal activation between young and aged entrained rats (E1) (p=.0478)
is seen following Tukey’s Multiple Comparison test and a trend (p=.0746) can be seen in
young rats between controls (C1) and entrained (E1) rats. However, no significant changes
in cFos labeled ChAT or vGluT labeled cells following food-paired stimulus for young or
old rats is seen following a two-way ANOVA or Tukey’s Multiple Comparison test.
4.5 Discussion
Studies in which cholinergic neurons are lesioned in the SI produce age-related
deficits in attentional tasks (M. Sarter et al., 2001). Because GABAergic and cholinergic
neurons in the SI are largely overlapping, an age-related deficits in both cholinergic and
glutamatergic neurons was expected. Interestingly, GABAergic PV+ neurons had the most
prevalent deficit in awareness and entrainment to a palatable conditioned stimulus in aged
rats compared to their younger counterparts, although slight attenuation of cholinergic
activation is present. Cortically projecting PV+ neurons from the BF have been shown to
play an important role in regulating cortical gamma band oscillations important in
awareness and arousal (T. Kim et al., 2015). Studies using optogenetic approaches have
highlighted a role for cholinergic neurons in reward/punishment schemes as well as reward
timing while PV+ GABAergic neurons have been attributed to behavioral state control and
arousal (S. C. Lin, Brown, Shuler, Petersen, & Kepecs, 2015). My data supports a role for
PV+ GABAergic neurons in arousal and attention related to a homeostatically relevant
stimulus, and presents a novel age-dependent deficit in PV activation of BF neurons upon
the presentation of a food-paired conditioned stimulus. This data suggests that PV neurons
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in the SI play an important role in recognizing homeostatically relevant cues, but this
behavior is severally disrupted during the aging process.
A separate set of neurons in the BF (SI) have recently been identified which
produce low tonic firing and cortical modulation consistent with projecting neurons (Avila
& Lin, 2014; S. C. Lin, Gervasoni, & Nicolelis, 2006; S. C. Lin & Nicolelis, 2008). These
neurons have been shown to play a key role in motivational salience and are considered
salient encoding. The identity of these neurons has been highly disputed and often mistaken
as cholinergic neurons; however, recent evidence suggests otherwise (S.-C. Lin, Brown,
Hussain Shuler, Petersen, & Kepecs, 2015). These neurons are thought to be potentially
GABAergic or glutamatergic neurons, although this is disputed (Henny & Jones, 2008;
Hur & Zaborszky, 2005). Analysis of glutamatergic (vGluT) and GABAergic (PV) neurons
using a salient conditioned stimulus supports the idea for PV projecting neurons as the
mystery neuronal subset. Further studies are needed to confirm whether all or most of these
activated BF neurons were cortically projecting.
The BF cell populations which have been analyzed have been implicated in arousal,
learning, and attention, and the disruption of these neurons during aging has been linked to
many neurological disorders, such as coma and Alzheimer's disease. Although, the BF is
known for the role its cholinergic neurons play in cognition, recent studies targeting
specific BF cell types have led to a new insights on cell-type-specific circuit mechanisms
during behavior. In my study, a conditioned salient stimuli approach has enable me to
determine changes in age-related behavior and neuronal dysfunction under which
noncholinergic BF neurons are key players. Thus, I have identified a behavioral approach
which influences GABAergic mechanisms (PV).
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Figure 4.1 Immunohistochemistry in the Basal Forebrain.
(A) A significant change between young and aged rats following food-paired
stimulus (E1) in PV+ activation within the basal forebrain. (B)(E)(H)
Representative image (10X) of cFos/PV+ double labeling (black arrow) in the
basal forebrain in young rat after the food paired stimulus (E1). (C)(F)(I) A
representative image (10X) of an old rat after the food paired stimulus (E1). (D)
Double labeled(black arrow) cFos/ChAT in the basal forebrain following
habituation (C1), Foor-paired stimulus training with no CS+ on day 7 (C1) and
Food-paired stimulus for 7 days (C2). No significant changes in basal forebrain
ChAT activation between young and old rats. (G) Double labeled(black arrow)
cFos/vGluT in the basal forebrain following habituation (C1), Foor-paired
stimulus training with no CS+ on day 7 (C1) and food-paired stimulus for 7 days
(C2). No significant changes in basal forebrain vGluT activation between young
and old rats.
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CHAPTER 5. AGE-RELATED CHANGES IN BF MICROGLIAL
ACTIVATION
Specific Aim 3: Investigate the role of orexin-microglial interactions as it
relates to age-related BF homeostatic function.
5.1 Rationale
The orexin system originates in the LH and projects to several regions in the
brain including the BF. Orexins are an excitatory neuropeptide originally discovered in
the late 1990s, which are involved in a broad range of homeostatic signaling including
appetitive behavior, wakefulness, and arousal (D. Frederick-Duus et al., 2007; Sakurai &
Mieda, 2011; Villano et al., 2017). It was later understood that two Orexins, OXA and
OXB, are involved in integrating a variety of homeostatic signals. Both OXA and OXB
are encoded by a single precursor polypeptide, named prepro-orexin (Kukkonen et al.,
2002). The presence of mRNA for both OXR1 and OXR2 was first discovered in the BF
using quantitative PCR and in situ hybridization (Marcus et al., 2001). Due to the BFCS
role in attentional processing, it was thought that the orexin system may play an
important role in biasing attentional resources towards external stimuli that are important
for homeostatic balance (Hagar et al., 2017). Thus, orexin inputs to the BFCS are thought
to provide anatomically important interactions that are particularly important in
functional roles involving arousal and attention, specifically for allocating importance to
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specific interoceptive cues related to external stimuli (J. Fadel & Burk, 2010b; Jim Fadel
& Frederick-Duus, 2008).
The ability to integrate environmental cues that are related to interoceptive status
combined with the broad range of functions influenced by the orexin system has earned
them their description as “physiological integrators”. This is supported by previous
studies that reveal an age-related decline of orexin function both at a molecular and
behavioral level leads to homeostatic dysfunction and a loss in cue-related homeostatic
behaviors (Kessler et al., 2011). Furthermore, inhibition of orexin expression using a
lentivirus preproorexin antisense, revealed that the loss of orexin expression in young rats
mimicked similar neurochemical and feeding behaviors seen in rats with age-related loss
of orexin suggesting that orexin loss is an important aspect in age-related homeostatic
dysfunction (Hagar et al., 2017).
Previous studies using immunofluorescence revealed expression of OXR1 by glial
cells and OX1R receptor is upregulated in microglia after murine controlled cortical
impacts models (Mihara et al., 2011). Thus, Orexin receptors are known to be located on
many cell populations as well as glial cells including microglia and may mediate
inflammatory responses in the BF via OXR1 and OXR2 (C. M. Duffy et al., 2019; Cayla
M. Duffy et al., 2015; Manich et al., 2019; G. J. Wright, Jones, Puklavec, Brown, &
Barclay, 2001; Gavin J. Wright et al., 2003). Moreover, recent studies reveal an agedependent relationship between orexin and microglial activation (Cayla M. Duffy et al.,
2015; Xiong et al., 2013). Immunohistochemical studies reveal an age dependent
increase in microglial activation (Harry, 2013; Ogura, Ogawa, & Yoshida, 1994a;
Overmyer et al., 1999). This suggests a potential role for orexin receptors in mediating
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inflammatory response (Ogura, Ogawa, & Yoshida, 1994b). Moreover, studies
implicating the role of orexins in microglial regulation suggest that orexins may produce
inflammatory changes which are neuroprotective against cognitive decline (C. M. Duffy
et al., 2019; Cayla M. Duffy et al., 2015; Xiong et al., 2013). Studies also suggest a
possible role for orexin receptor mediated microglial inflammation during aging and agerelated cognitive decline (Frank et al., 2006; Ogura et al., 1994b; D. G. Walker, DalsingHernandez, Campbell, & Lue, 2009). In our study, I propose that the loss orexin causes
morphological changes in microglial indicative of a pro-inflammatory state.
5.2 Hypothesis
Previous work in our lab has demonstrated a potential role for orexin, in
mediating physiological function, and in mediating attention as it relates to homeostatic
status in the basal forebrain during aging. Our lab has demonstrated that the knock down
of orexin expression in young rats, mimics similar cognitive and attentional deficits in
age rats suggesting that the loss of orexin innervation seen in aged individuals is linked to
the mild cognitive deficits manifested as one ages. My previous aims have targeted the
relationship between attentional processing of salient stimuli and the BF afferent and BF
local neuronal activation during aging. To assess the potential role of orexin-mediated
glial regulation in the BF, I knockdown of orexin expression and examine the
morphological changes in microglia and cytokine release in the BF and PFC, a major
region which receives both LH and BF projections, of young rats. I hypothesize that
study will demonstrate that the loss of orexin mediation on microglia produces a
dysfunction inflammatory effect, normally seen in aged animals, in brain regions which
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receive robust orexinergic input. Thus establishing a role for orexin induced
neuroprotection.
5.3 Approach
All experiments were carried out in accordance with IACUC approved protocols.
Experiments were carried out in two separate batches, one of which animals were
entrained. All experiments were conducted using young (3-4 months, 250-300g) or aged
(26-28 months, 450-550g) male Fisher 344/Brown Norway F1 hybrid rats (National
Institutes of Aging Colony, Baltimore, Maryland, USA). All Animals received lentiviral
injections following Habituation for 7 days and were given food ad libitum followed by
an 80% diet restriction and kept on a regulated light:dark cycle (12:12 hr) during the
duration of the experiment (Figure 5.1).
5.3.1 Stereotaxic Surgery and Lentiviral Injection
All animals were anesthetized using isoflurane (Piramal Critical Care Inc.,
Bethlehem, PA, USA) using E-Z anesthesia system (Euthanex Corps, Palmer, PA, USA).
Animals were mounted on stereotaxic surgical device (Stoelting, Dale, IL, USA).
Following sterilization, an incision is made, and a dremel tool was used to drill two holes
for bilateral injection of the lentivirus (LV-preproorexin antisense) into the LH (Young:
AP -2.5 mm, L ±1.2 mm, and DV -9.0 mm). This lentivirus vector was produced by
transfecting human embryonic kidney (HEK) 293T cells with a transgene expression
cassette (LV-PGK-ip-preproorexin-IRED-GFP-WPRE), an envelope cassette, a
packaging cassette (pCMVpR8.92), and a vector cassette (HIV-1 Tat-dependent vector)
which combined are able to transfect neuronal and glial cells with an antisense designed
to knockdown preproorexin expression, a precursor to the orexin neuropeptides.
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Figure 5.1 Timeline of lentiviral injection experiment on young rats (n=32). Rats were
further divided into 2 subcategories based on lentiviral injection (control; LV-GFP)
(SPWG-OX; LV-PPOX).
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5.3.2 Entrainment
Following handling during day 8-14, rats were habituated in bowls for 1 hr per day
until day 28 in which both controls (LV-control; n=8) and animals which received the
preproorexin antisense (LV-preproorexin; n=8) were trained with a conditioned stimulus
(bacon softie/darkness) and tested for feeding latency. During day 28-35 rats were tested
daily at the same time while on an 80% food restricted diet. On day 35 animals were
perfused with 4% paraformaldehyde 1 h after the completion of daily bowl habituation.
5.3.3 Trans-Cardial Perfusion and Tissue Collection
All experiments were completed with animals deeply anesthetized with isoflurane
and sacrificed. Brains were extracted and half the brain was placed directly on dry ice and
half post-fixed in a 4% paraformaldehyde solution. The flash frozen half of the brain was
then stored at -80ᵒ C to await further processing, and the post-fixed half of the brain was
blocked into 3 sections and sliced using a vibratome (Electron Microscopy Sciences, OT4000) into 50 micron thick slices. The slices of brain tissue were collected and free
floated in six wells of the 1X Tris-buffered saline, then transferred to anti-freezing
solution for long term storage.
5.3.4 Immunoperoxidase following Lentiviral Injection in the LH
Post-fixed brains stored in 4% paraformaldehyde for 24 hr were coronally
sectioned (50 microns) using a vibratome. Rat brains injected with the lentivirus
containing preproorexin antisense (LV-PPOX) or lentivirus containing GFP and only the
GFP gene (LV-GFP) were double labeled for rabbit αIb1A (1:5000; Wako Pure Chemical
Industries; Osaka, Japan; Cat# 019-19741; Lot# PTR2404), and either goat α-Orexin-A
(OXA; 1:500; Santa Cruz Biotechnology Inc.; Dallas, TX, USA; Cat.# sc80263), goat α-
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ChAT (1:3000; Millipore, Temecula, CA, USA;, Lot# 2762374, Cat#AB144), or mouse
α-Parvalbumin (PV; 1:3000; Sigma, Saint Louis, Missouri, USA; Cat#P3088, Batch#
016MA847V) to identify microglia, and orexin neurons, cholinergic neurons, or
parvalbumin positive neurons, respectively. Tissue was developed using DAB (SigmaAldrich co., St. Louis, MO, USA, Lot#MKCK2487) to produce microglial labeling along
side either OXA, ChAT, or Parv neurons. For all immunoperoxidase slides, images were
visualized using the Nikon Eclipse was fitted with CoolSNAP digital camera (Roper
Scientific, Trenton, NJ, USA) and visualized using with the IP Labs Software
(Scanalytics; Trenton, NJ, USA).
5.3.5 Assays
For brain homogenates, punches were taken using a freezing microtome and the
rat brain atlas. Tissue was immediately weighed and placed in active lysis buffer solution
on ice and homogenized using .5mm Zirconium Oxide beads (Next Advance; Troy, NY,
USA; Cat# ZROB05) in a safe-lock Eppendorf tube which is then placed in a bullet
blender (Next Advance; Troy, NY, USA; Cat# G14G15) for 5 minutes at speed 10 in
4ᵒC. Tubes are aliquoted into Eppendorf tubes (50ul each) and immediately placed in 80ᵒC freezer to await ELISA or BCA Protein Assay. BCA working reagent is determined
and working reagent is prepared on a plate along with tissue samples which are diluted at
1:12.5 in HPLC grade water in Eppendorf tubes. To a sample plate, tissue sample, and
working reagent is added to each well alongside a set of standards. Plate is then placed in
oven, and then cooled for 15 minutes outside the oven before being read using a Biotek
Synergy 2 Plate Reader (Biotek instruments Inc.; Winooski, VT, USA; Cat #7131000).
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For the Elisa, brains homogenates of animals were analyzed using a 12-Plex
Th1/Th2 Bio-Plex kit (Bio-Rad Laboratories Inc.; Cat # 171K1002M; USA). Brain
Homogenates were thawed and diluted to 1:3 with diluent. To a plate, magnetic beads,
standards and samples, the detection antibody and SAPE were added to each well
following washes. The plate was read using a Luminex Bio-Plex Multiplex plate reader
that uses high photomultiplier voltage to detect cytokines. Results were interpreted from
a logarithmic standard curve.
5.4.6 Statistic analysis
Differences in latency to feed and immunohistochemistry were tested by a oneway ANOVA post hoc test with significance p < .05. All statistical tests were done using
GraphPad Prism version 5.02 or 9 (GraphPad Software Inc.; San Diego, CA). BCA
protein assays were analyzed using Excel and protein contents (ug/ml) were then
interpolated in GraphPad Prism 9 using a standard curve. ELISA data (pg/ml) was
normalized to protein content (ug/ml) and graphed using an analysis of variance
(ANOVA) with significance set at p < 0.05. Cytokines were analyzed as one-way
ANOVA or paired/unpaired t-test.
5.4 Results
5.4.1 Feeding Latency and Food intake
To test whether the administration of LV-PPOX changed food intake and body
weight of animals, animals were weighed and food intake was taken daily at the same
time (11:00hr). Previous research in our lab has shown that administering LV-PPOX has
a significant effect on feeding latency and food intake (Danielle Frederick-Duus, 2008;
Hagar et al., 2017). The administration of LV-PPOX into the LH, was confirmed to have
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a significant change decrease in food intake (P <.0001; t=12.84, df= 30) (n=16) following
an unpaired t-test (Figure 5.2). Analysis using multiple unpaired t-tests Similar increases
in feeding latency has been shown following injection of LV-PPOX into the LH (n=8)
(p=.0003; t= 7.977 df=14; Day 7; Figure 5.2 C, D) .

Figure 5.2 Food Intake and Feeding Latency following LV-PPOX
(A) A Significant difference between LV-PPOX and LV-Control groups (p < .0001). A
graph showing average food intake between LV-PPOX and LV-Control administered
animals reveals a defined decrease in food intake. (C) On day 7, following 6 day of foodpaired stimulus entrainment, a significant difference between latency to approach and
consume a bacon softie (feeding latency) of animals administered LV-PPOX and LVControl (t-test; p=.003) into the LH and (D) a significant difference between treatment
groups and time following a multiple t-tests where LV-PPOX significantly reduced
latency to feed on Days 3 (p=.0043), 4 (p=.0122), 5 (p=.0348), 6 (p=.0094), and 7
(p=.0003).
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5.4.2 Age-related Changes in Microglia Morphology in the BF
Preliminary work our lab using aged and young animals has confirmed work
which suggests age-related microglial change. Single Ib1A-labeled (microglia) cells were
counted under 20X magnification using two different sections of young and aged (n=8)
BF sections. In addition, the labeled cells where manually analyzed for morphological
differences in which M1 is categorized by short processes and large cell bodies and M2 is
categorized by long processes and medium to small cell bodies. Unpaired t-test on the
average number of both sections in the BF revealed no significant changes in total
microglia amount (unpaired; p= .5248; df= 14; t= 2.549), but do exhibit a change in
morphology, particularly an increase in M1 phenotype microglia, characterized by short
processes and large cell bodies (unpaired; p= .0718; df= 14; t= 1.491) (Figure 5.3). This
data is supported by previous research which has identified a change in microglial
morphology between young and aged animals (Spittau, 2017; VanGuilder et al., 2011).
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Figure 5.3 Changes in Microglial Morphology in Young and Aged Rats
(A) No Significant difference between total count of microglia in aged (26-28 month)
and young (3-4 month) groups (p =.5248). (C) A small trend in M1 morphology
between aged (26-28 month) and young (3-4 month) groups (p =.0718). (B)(D) A graph
showing microglia morphology via single labeled (Ib1A) cells in aged and young
animals reveals exemplifies a difference in microglia morphology.
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5.4.3 Changes in Microglia Morphology in the BF following LV-PPOX
Double labeling for OX-A-Ib1A (Orexin and microglia) cells were analyzed to
count microglia amount and Orexin presence/proximity under 20X magnification using
two different sections of young and aged (n=16) BF sections (Figure 5.4). The orexin
(OX-A) labeled cells revealed a decrease in orexin fibers. The decrease in Orexin fibers
following LV-PPOX administration confirms the lentiviruses ability to downregulate
orexin expression in young animals. The Ib1A (microglia) labeled cells where analyzed
morphologically in which M1 is categorized by short processes and large cell bodies and
M2 is categorized by long processes and medium to small cell bodies. Unpaired t-test on
the average number of both sections in the BF revealed no significant changes in total
microglia amount following LV-PPOX (unpaired; p= .2412; df= 30; t= 1.196). However,
following the analysis of Ib1A cell morphology, microglia were found to exhibit a
significant increase in M1 phenotype characteristics, including larger cell body and
shorter processes (unpaired; p= .0280; df= 30; t= 2.310). This data is similar to aged
animals which exhibited an increase in M1 phenotype suggesting that administration of
LV-PPOX into the LH of young animals can create similar phenotypic changes in
microglia morphology as aged animals.
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Figure 5.4 Changes in Microglial Morphology following LV-PPOX
(A) No Significant difference between total count of microglia in LV-Control and
LV-PPOX groups in young animals (3-4 months) (p =.2412). (C) A significant
increase in M1 morphology between microglia in LV-Control and LV-PPOX
groups in young animals (3-4 months) (p =.0280). (B)(E) Two pictographs showing
microglia morphology and orexin fiber labeling in LV-PPOX (C)(F) and LVControl groups reveals LV-PPOX downregulates orexin expression of young
animals 4 weeks after administration into the LH.
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5.4.4 Cytokine changes in the BF following LV-PPOX
Four weeks after LV-PPOX or LV-Control injection of young rats, the BF was
homogenized and contents of the pro-inﬂammatory and anti-inflammatory cytokines was
observed using an ELISA assay (Figure 5.5). Following a t-test, the expression of TNFα
(unpaired; p= .0691; df= 14; t= .5614) showed a trend of increased release in the BF of
young animals administered LV-PPOX compared to controls. Analysis of other proinflammatory cytokines, such as IL1β, IL-6, IFN-γ, and IL-12 did not show any
significant changes in expression. Additionally, analysis of the anti-inflammatory
cytokine, IL-10, showed no significant changes between LV-Control and LV-PPOX
group of young animals.

Figure 5.5 Cytokine changes in the BF following LV-PPOX
(A) A significant increase in TNFα between LV-Control and LV-PPOX groups in
young animals (3-4 months) (p =.0691). (B) IL1β (C) IL-6 (D) IFN-γ (E) IL-12 (F) IL10 did not show significant changes between LV-Control and LV-PPOX groups in
young animals (3-4 months) in the BF 4 weeks after administration into the LH.
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5.4.5 Cytokine changes in the PFC following LV-PPOX
Four weeks after LV-PPOX or LV-Control injection of young rats, the PFC was
homogenized and contents of the pro-inﬂammatory and anti-inflammatory cytokines was
observed using an ELISA assay (Figure 5.6). Following a t-test, the expression of TNFα
(unpaired; p= .0040; df= 14; t= 3.484) and IL-6 (unpaired; p= .0016; df= 14; t= 3.902)
showed a significant increase in release in the BF of young animals administered LVPPOX compared to LV-Controls. Analysis of other pro-inflammatory cytokines, such as
IL1β, IFN-γ, and IL-12 did not show any significant changes in expression. Additionally,
analysis of the anti-inflammatory cytokine, IL-10, showed no significant changes
between LV-Control and LV-PPOX group of young animals.

Figure 5.6 Cytokine changes in the PFC following LV-PPOX
(A)(C) A significant increase in TNFα and IL-6 between LV-Control and LV-PPOX
groups in young animals (3-4 months) (p =.004). (B) IL1β (D) IFN-γ (E) IL-12 (F)
IL-10 did not show significant changes between LV-Control and LV-PPOX groups in
young animals (3-4 months) in the PFC four weeks after administration into the LH.
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5.5 Discussion
Orexin has been described as a key neuropeptide which regulates fundamental
brain functions, including arousal, attention, appetite, and cognition. The dysregulation of
orexin signaling plays an important role in aging and age-related diseases, such as AD
(Liguori, 2017). Research has shown that excessive or inhibition of orexinergic signaling
leads to a disruption in cognitive decline, sleep disturbance, dysregulation of microglial
signaling, and interrupts Aβ deposition and aggregation (Um & Lim, 2020). This
suggests that the imbalances of orexin signaling can contribute to the pathology seen in
aged individuals and AD patients. In models of aged animals, our lab has previously
shown that orexin is lost which contributes to age-related cognitive decline (Kessler et
al., 2011). Additionally, we have demonstrated that the orexin system plays an important
role in regulating cognitive function and that aging is associated with dramatic reductions
in the number of orexin neurons and deficits in activation of cortical, LH and circuitry by
homeostatically-relevant stimuli. (Calva et al., 2018, 2020; J. Fadel & Burk, 2010b;
Hagar et al., 2017; Kessler et al., 2011).
Recent studies have reported that orexin may exert an important role in
neuroprotection by reducing apoptosis and inflammation (Irving et al., 2002;
Sokołowska, Urbańska, Namiecińska, Biegańska, & Zawilska, 2012). Studies using
transgenic mouse model of neurodegeneration, orexin/ataxin-3 mice, link orexin loss to
neurodegeneration, memory and cognitive deficits, and neuroinflammation. In
conjunction, studies describing age-related changes in microglial morphology may
undergo age-dependent degeneration due to their loss of neuroprotective function there
by contributing sporadic AD (Streit, Braak, Xue, & Bechmann, 2009; Streit et al., 2004).
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Moreover, aged microglia have been characterized have been characterized by their
reduced processes and increased proinflammatory cytokines, such as TNFα, IL1β and IL6 (Sierra, Gottfried-Blackmore, Mceven, & Bulloch, 2007). Altered microglia
morphology and reduced arborization have been reported in the human brain during
aging and in patients diagnosed with AD (D. S. Davies, Ma, Jegathees, & Goldsbury,
2017).
The activation of BF circuitry by orexinergic neurons, and their role in arousal
and cognition, particularly attention, are relatively well known. Recent reports have
shown that orexin-deficient mice under a high fat diet have impaired cognition and
increased microglial activation in the cortex (C. M. Duffy et al., 2019). Orexinergic
neurons and both orexin receptor subtypes are distributed in the BF and cortex, and
orexin has been shown to modulate the BFCS. Studies have shown an upregulation in
microglia in the cortex in response to inflammation caused by impairment (Mihara et al.,
2011). This suggests a potential role for orexin-glial communication in the BF and cortex
which may be disrupted with age. Following the inhibition of orexin using LV-PPOX, we
demonstrated changes in microglial morphology similar to that of aged animals and
orexin reduction will contribute to an increase inflammatory cytokines, particularly in the
PFC.
It should be noted that the approach, ELISA assay of brain homogenates, used
did not distinguish the origin of cytokine release. Other glia, including astrocytes, are also
capable of contributing to the cytokine increase in the PFC and BF. Thus, further studies
defining the role of astrocytes in this mechanism are necessary. Additionally, I expected
to see greater activated microglial expression in the BF of LV-PPOX treated rats
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compared to LV-Controls. However, considering that inputs into the PFC include BF
efferents and orexinergic efferents from the LH, it is not surprising to see a greater effect
in the PFC (Figure 5.7). Further studies will be essential in order to broaden our
understanding of the role of aged microglia in the relationship between the LH
originating orexin neurons and microglia residing in brain regions with heavy orexinergic
input, such as the PFC and BF, to elucidate the impact of aging on microglial functions.
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CHAPTER 6. GENERAL CONCLUSIONS
Aging is characterized by mild neuronal degeneration which leads to mild
memory loss, attentional deficits, homeostatic imbalance and sleeping abnormalities. BF
neurons are particularly vulnerable to dysfunction and degeneration in aged humans and,
more dramatically, in diseases such as AD. This suggests that dysfunctional anatomical
correlates of the BF, specifically in the SI/NBM, may be a key component in the spread
and development of mild cognitive impairments and, in more severe cases, AD. This
study investigates age-related changes in basal forebrain afferent neuronal and cell
populations to identify vulnerable populations involved in age-associated cognitive
decline and dysfunction. Specifically, my study compared neuronal afferent activation,
BF neuronal activation and glial populations to identify anatomical factors susceptible to
age-related homeostatic dysfunction in the BF.
I first looked at changes in activation of BF inputs from several brain regions
including the PFC, ILC, Cl, CeA, LH, NAc, and VTA. The BF plays a significant role in
the information processing and integrating signals from different afferent regions. These
projections make contact with several populations in the BF including BFCS,
glutamatergic neurons, GABAergic neurons and glial populations, such as microglia. We
know the loss of BF neurons can effect neural networks which rely on BF input to
provide necessary communication attributed to the cognitive and homeostatic balance
necessary for proper function. It is also possible that the dysfunctional signaling
contacting the local BF neurons may contribute in some way to neuronal dysregulation
and degeneration. Regions which send inputs to the BF may be involved in the circuits
which seem to manifest the neuronal dysfunction and degeneration in aging and age114

related diseases, such as AD. However, it is still not known how these regions are
effected during normal age relate changes and there is still much to learn about afferent
neuronal populations which make contacts with the BFCS and local cell populations. We
hypothesize that age-related attentional deficits related to the attentional processing of
homeostatically-relevant stimuli is associated with dysfunctional neuronal activation of
specific BF afferents. We have revealed several circuit motifs vulnerable to age-related
dysfunction, including the PFC, LH, NAc, and VTA, which will enable future anatomical
studies to define specific cell signaling mechanisms that are effected by aging and agerelated diseases (Figure 1.1). We have also show that a deregulation in activation of PV+,
GABAergic neurons, is associated with processing of the homeostatically-relevant
stimulus which is attenuated with aging revealing a potential role of GABAergic neurons
in age-related cognitive decline. PV+ GABAergic neurons have been attributed to
behavioral state control and arousal (S. C. Lin, Brown, Shuler, Petersen, & Kepecs,
2015). Our data supports a role for PV+ GABAergic neurons in arousal and attention
related to a homeostatically relevant stimulus, and presents a novel age-dependent deficit
in PV activation of BF neurons upon the presentation of a food-paired conditioned
stimulus.
An interesting hypothesis is that the manifestation of age-related deficits may
share common underlying neurobiological mechanism, possibly through an anatomical
region involved in homeostasis which regulates the activity of brain regions which
mediate behavioral and cognitive responses to physiological imbalances, and these
interactions may be impacted in aging. Our lab has shown that orexin neuropeptides,
which have been shown to degrade during aging, play a pivotal role in maintaining
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homeostatic balance and exert influence over the PFC, NAc, BF, and VTA. Moreover,
orexin may exert an important role in neuroprotection exerted by microglia by reducing
apoptosis and inflammation, and that during aging microglial morphology may undergo
age-dependent degeneration contributing to their loss of neuroprotective function (Irving
et al., 2002; Streit et al., 2009, 2004). We have shown that downregulation of orexin via
LV-PPOX can mimic similar changes, including the presence of microglia with reduced
processes and increased proinflammatory cytokines, such as TNFα, and IL-6. This
suggests a potential role for orexin-glial communication in the BF and cortex which may
be disrupted with age. Thus the orexin system has been shown to influence changes in
response to a homeostatically-relevant stimuli which is then attenuated with age. BF
inputs which have an intimate relationship with the orexin system as it relates to
processing/activation in response to homeostatically relevant salient cues show
attenuation during aging. The loss of orexin mimics feeding latencies, activational
changes, and microglial changes seen in aging. Thus, the orexin system and the BF play
a pivotal role in the age-related cognitive and functional deficits. Further studies will be
essential in order to broaden our understanding of the role orexin neurons during aging as
it relates to BF neuronal and glial dysfunction. However, the results from this study have
contributed toward the efforts to identify targets of age-related dysfunction which may
play a role in age associated MCI and homeostatic dysfunction exacerbated during agerelated neurodegenerative diseases, such as AD.
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